The Role of Proteomics and Genomics in the Development of Colorectal Cancer Diagnostic Tools and Potential New Treatments.

Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice ACS Pharmacol Transl Sci . 2025 Apr 10;8(5):1227–1250. doi: 10.1021/acsptsci.4c00686 Search in PMC Search in PubMed View in NLM Catalog Add to search The Role of Proteomics and Genomics in the Development of Colorectal Cancer Diagnostic Tools and Potential New Treatments Gaurav Paraskar Gaurav Paraskar 1 School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India Find articles by Gaurav Paraskar 1 , Sankha Bhattacharya Sankha Bhattacharya 1 School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India Find articles by Sankha Bhattacharya 1, * , Anitha Kuttiappan Anitha Kuttiappan 1 School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India Find articles by Anitha Kuttiappan 1, * Author information Article notes Copyright and License information 1 School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India * Email: [email protected] . * Email: [email protected] . Received 2024 Nov 26; Accepted 2025 Apr 3; Revised 2025 Mar 14; Collection date 2025 May 9. © 2025 American Chemical Society PMC Copyright notice PMCID: PMC12070319  PMID: 40370990 Abstract The complex molecular mechanisms involving genetic and epigenetic modifications contribute to colorectal cancer (CRC), which remains a significant threat to world health. This review elucidates the role of proteomics and genomics in the progression, diagnosis, and treatment of colorectal cancers. All potential key pathways involved in CRC, including WNT, MAPK, PI3K, and TGF-β pathways, are reviewed with a systematic analysis, concluding with their involvement in tumorigenesis and therapeutic resistance. Emerging next-generation sequencing technologies revealed critical mutations that are relevant to CRC development. Proteomics has contributed to identifying biomarkers and post-translational modifications that hold promise for targeted therapies. Recent technological advances have provided functional insights into protein signaling networks and pathways through mass spectrometry and integrated proteogenomic approaches. This work emphasizes biomarker-driven translational efforts that integrate genomic insights with protein expression profiles to refine personalized treatments. The application of innovations in liquid biopsy and computational biology advocates for precision medicine paths to improve the outcomes for CRC. Now, pharmacoproteomics offers novel domains for drug discovery and resistance management and serves as a foundation for comprehensive CRC treatment paradigms. Keywords: Colorectal Cancer (CRC), Proteomics and Genomics, Molecular Pathways, Biomarker Discovery, Targeted Therapies, Precision Medicine 1. Introduction Colorectal cancer ranks as the third most prevalent malignancy worldwide, with approximately 1.9 million new cases documented in 2020 and a projected rise to 3.2 million by 2040. Recent studies have identified subsets of cancer of unknown primary origin (CUP) that exhibit characteristics similar to colorectal cancer, such as CUP with a colon-cancer profile (CUP-CCP), which displays adenocarcinoma histology and a specific immunohistochemical pattern (CK20+, CDX2+, CK7−). Despite the absence of an identifiable primary tumor in the colon or rectum, CUP-CCP responds favorably to colorectal cancer treatments, offering a more favorable prognosis compared with typical CUP cases. The recognition and treatment of these CUP subsets as colorectal cancers may contribute to the observed increase in colorectal cancer incidence rates. Furthermore, significant geographical variations exist in incidence and mortality rates, with higher rates observed in regions such as Europe and Australia/New Zealand. 1 However, it is still highly preventable because of the pervasive implementation of screening programs and improved understanding of its molecular pathogenesis. Key mutations and epigenetic changes that occur early in the development of CRC have been identified through research on the development and progression of CRC in fruit flies, genetically engineered mice, and tissue culture systems. Furthermore, the Wnt, EGF receptor, TGF-β, and PI3K pathways have been identified as the most frequently altered pathways in sporadic and hereditary CRC. Technology advancements and the development of multiplexed assays for the detection of alterations in tumor biomarkers have resulted in the widespread implementation of tumor profiling using next-generation sequencing in clinical practice. Actionable alterations have become the focus of various types of cancer, including CRC, because of the rapid development of personalized targeted treatment options such as small molecule inhibitors and monoclonal antibodies that interfere with the molecular activity of specific alterations involved in tumorigenesis. Liwei Ma et al. 2 review that the implementation of liquid biopsy and the analysis of cell-free DNA has enhanced patient stratification and treatment monitoring, which has the potential to positively impact patient survival. The widely used tumor profiling panels extensively interrogate CRC-associated and other alterations, including point mutations, insertions and deletions, fusions, and amplifications of genes implicated in CRC pathogenesis and treatment. 3 Validation studies of existing profiling panels on CRC specimens demonstrate their utility in a wide range of applications, including breaking down clinical samples into individual tumor profiles and matching them with FDA-approved treatments or clinical trials offering treatment options targeting detected alterations. 4 Despite the promise of tumor profiling, it is unlikely to be used as a stand-alone approach. Rather, it should complement the recent advances in therapeutic applications integrating with the existing diagnostic methodologies. CRC is one of the most prevalent malignancies globally. With increasing incidence and mortality rendering it the second primary cause of cancer-related deaths worldwide, CRC poses rising socioeconomic challenges for most countries. As noted by Kazeem Adefemi et al., 5 following the launch of the National Colorectal Cancer Screening and Prevention Program in Taiwan in 2004, there has been a rise in the detection rate of precancerous lesions, leading to more effective treatments. Nonetheless, it is projected that 19,779 fresh cases will be identified in 2024, resulting in 7,869 deaths and adding to the increasing healthcare strain. Even though significant progress has been made in treatment, the roles of insurance would be beneficial to bridge the gap in the high- and low-CSS groups. A 5-year CRC-specific survival (CSS) and 5-year overall survival (OS) were 78% and 63% in 2008, yet decreased to 72% and 62% in 2020. With further comprehension of tumorigenesis and the development of novel technologies, proteomics and genomics have provided tremendous power to promote precision medicine in various malignancies. 6 This work provides an overview of the function of proteomics and genomics in CRC treatments, including efforts to search for prospective biomarkers for early detection and recurrence prognosis and the prediction of therapeutic resistance and response. In light of the many shortcomings indicated in the current body of knowledge regarding the genomic and proteomic profiling of CRC, our manuscript has also striven to contribute toward addressing crucial knowledge gaps pertaining to how specific proteomic and genomic alterations interplay to influence CRC progression, treatment resistance, and prognosis, all in the backdrop of the translational possibilities these insights provide into the dominion of clinical practice; we furnish a detailed account of molecular subtypes based on high-throughput genomic and proteomic data and efficiency delineation of important signaling pathways such as Wnt, PI3K, and MAPK and their roles in tumorigenesis, therapeutic resistance, and targeted treatment strategies with support from state-of-the-art methodologies including mass spectrometry for quantifying proteins, high-throughput sequencing for deciphering genomic alterations, and integration of pharmacogenomics and pharmacoproteomics to excel in personalized treatments, rounding up with emerging biomarker-driven technologies, which connect molecular diagnostics with therapeutic applications, thus paving the way in developing more precise, potent, and patient-specific strategies for CRC management. 2. Principles of Proteomics and Genomics Puthen Veettil Jithesh et al. 7 review that genomics refers to the study of genomes, the complete set of DNA within an organism, including all its genes. Within multicellular organisms, genomes contain heritable information that is passed from one generation to the next. Genomes also include noncoding sequences that do not encode proteins, although some of these play important functions in regulating cellular activity. 8 The pioneering initiatives in genomics were the mapping and sequencing of the genomes of model organisms, such as yeast, fruit fly, nematode worm, zebrafish, and mouse, and then the sequencing of the human genome. A genome is the complete genetic material consisting of the DNA and RNA of an organism. In human individuals, the genetic material is present in the form of DNA, a biopolymer consisting of nucleotides. 9 A genome contains all genes and other sequences of nucleotides in the DNA of an organism. Genomics is the study of the genome, and it also includes the structural and functional variations in the genetic material, interactions of genes with the internal environment and external environment of the organism. 10 Genomics also incorporates the imaging of the genome, proteome, and metabolome at various levels, such as the organ level, tissue level, cell level, and single cell level. The advances in the field of genomics are predominantly propelled by innovations in DNA sequencing technology, bioinformatics tools, and genomics platforms. Genomics provides the foundation for proteomics and other omics. 11 Genomics answers queries like “What do we have?” and “What can it do?” by a genomic scan of microarray patterning for different organisms. It provides the repertoire of genes in an organism to construct phylogenetic trees between organisms. Qi, L., et al. stated that the large-scale and high-throughput analysis of proteins was performed with the aid of bioinformatics tools and proteomics platforms. It is the second-generation gene-focused methodology, and it is also known as protein omics. 12 Although genomics provides a broad catalogue of genes, it does not provide direct information on which genes or their products are expressed. The array of expressed proteins and their states in particular tissues, organs, or a specific cell type at a particular time is known as the proteome of that tissue, organ, or cell type. With the identification and sequencing of the genomes of various organisms, it became possible to infer the corresponding proteins, which are the products of these genes. So far, entire genomes of more than 200 organisms ranging from low microbes to humans have been sequenced and entered the public domain. 13 Genome annotation is the prediction of the corresponding proteins, and it generates a catalogue of the predicted proteins, which is a protein database for comparative secondary structure modeling. Several pieces of information regarding treatment type and targeted pathways are mentioned in Table 1 . Table 1. Fundamentals of Proteomics and Genomics. Treatment Type Description Targeted Pathways Notes References Chemotherapy Systemic treatment using cytotoxic drugs Various pathways Commonly used in advanced stages; resistance is a concern. ( 14 ) Targeted Therapy Drugs that specifically target molecular alterations EGFR, VEGF, BRAF, PI3K Examples include cetuximab (anti-EGFR) and bevacizumab (anti-VEGF). ( 15 ) Immunotherapy Enhances the immune system’s ability to fight cancer Immune checkpoints (e.g., PD-1/PD-L1) Emerging as a treatment option; effective in specific CRC subtypes. ( 16 ) Radiation Therapy Uses high-energy rays to kill cancer cells Localized treatment Often used in conjunction with surgery. ( 17 ) Surgery Resection of tumor and surrounding tissue N/A Primary treatment for localized CRC; may be combined with adjuvant therapies. ( 18 ) Open in a new tab 2.1. Principles of Genomics in CRC Colorectal malignancies CRCs are caused by genetic and epigenetic alterations in the colonic epithelium. These alterations lead to its transformation through a progression from adenoma to carcinoma, passing through several histological stages and accumulating a number of driver mutations within key oncogenic and tumor suppressor genes. 19 CRC is heterogeneous at both the genetic and epigenetic levels. Analyses uniformly detect oncogenic mutations in KRAS and TP53 and tumor suppressor mutations in APC and PIK3CA. In addition to these four canonical mutations, cancer-specific mutations in over 10 additional genes are evident across individual cancer types, providing further comprehension of individual tumor abnormalities. Base substitutions, minor insertions and deletions, copy number alterations, and large structural variations are the most prevalent classes of mutations detected in individual tumors, each with genetic predisposition, mutagenic processes, and associated genes. 20 CRC-specific driver genes including CTNNB1, KRAS, and APC are specifically mutated in MSI-H, CIN, and CIMP CRC subtypes, respectively. 21 Pan-cancer analyses demonstrate that individual mutations in TP53 cause CRC to be more aggressive with higher tumor stages and grades. Aberrant transcriptional and post-transcriptional regulations are also enriched in CRC, as shown by transcriptome sequencing, microRNAs, and long noncoding RNAs. CRC-associated variants of noncoding regions identified by epidemiological studies and miRNA binding sites predicted by algorithms have been experimentally validated to impact the expression of target genes in CRC, adding another layer of complexity to the understanding of oncogenesis. Despite the advancements in CRC research, comprehending how ncRNAs are implicated in CRC is elusive. 22 There have been only a few reports characterizing whole-exome and whole-genome sequencing data of CRCs. The findings include a study demonstrating that unknown mutation signatures are enriched in noncoding sequences of CRCs and a frequent observation of mutations located within binding sites of epigenetic regulators. However, due to extensive biotechnological difficulties of analysis, there has not been any large cohort deep sequencing investigations of the entire transcriptome in CRC. 23 Table 2 summarizes pivotal signaling pathways implicated in colorectal cancer, highlighting key genes such as APC, KRAS, and SMAD4, along with their roles in cell growth, differentiation, apoptosis, and survival, emphasizing their relevance to tumorigenesis and potential therapeutic targeting. Table 2. Key Signaling Pathways in Colorectal Cancer: Genetic Alterations and Functional Roles. Pathway Key Genes Involved Function References Wnt Signaling APC, β-catenin Regulates cell growth and differentiation. ( 24 ) MAPK Pathway KRAS, BRAF, MEK Controls cell proliferation and apoptosis. ( 25 ) PI3K Pathway PIK3CA, PTEN Involved in cell growth and survival signaling. ( 26 ) TGF-β Pathway SMAD4 Regulates cell cycle and apoptosis; tumor suppressor. ( 27 ) EGF Pathway EGFR, KRAS Mediates cell signaling for growth and division. ( 28 ) Open in a new tab CRC is a heterogeneous disease that originates through a stepwise accumulation of genetic and epigenetic alterations, affecting critical cellular pathways. Recent studies on the molecular comprehension of CRC have elucidated its subgrouping through crucial genetic alterations that can also impact treatment decision-making. 29 Activating mutations in oncogene KRAS are early events in the development of CRC through the adenoma-carcinoma sequence. KRAS mutations are also significant biomarkers that may guide therapy with anti-EGFR agents. The guanine nucleotide exchange factor SMAD4 thereby modifies the transformation of APC-deficient cells into an adenoma. The involvement of SMAD4 mutations in CRC has been investigated by the characterization of genetic alterations in CRCs with a focus on SMAD4. 21 Aiming for CRC-related mutations, targeted deep sequencing was performed on resected specimens using a custom ion amplicon designer kit, while copy number alterations were detected by Copy Number Assays. All tumor specimens were screened for KRAS mutations, in which a percentage of patients with CRC mutations. 30 Furthermore, the involvement of SMAD4 in CRC was revealed using colorectal cancer cell lines with SMAD4 loss. SMAD4 was shown to attenuate the KRAS-driven transcriptional program and promote punctual entry into the G1/S phase. The CRC cell lines used were enumerated to facilitate the further investigation of SMAD4-related phenotypes in CRC. 31 Whole-exome sequencing results from matched samples were derived, classifying tumors into parallel and variant groups according to their mutational phase and copy numbers. The genes such as APC, KRAS, TP53, PIK3CA and BRAF there prevalence and the role in the treatment of the CRC are mentioned in the Table 3 are as follows. Table 3. Key Genetic Alterations in Colorectal Cancer (CRC): Prevalence, Roles, and References. Gene Type Prevalence Role in CRC References APC Tumor Suppressor 70–80% of sporadic cases Initiating event in tumorigenesis; regulates β-catenin. ( 33 ) KRAS Oncogene ∼40% of cases Early event in adenoma-carcinoma sequence; guides anti-EGFR therapy. ( 34 ) TP53 Tumor Suppressor ∼50% of cases Maintains genomic stability; prevalent alteration in CRC. ( 35 ) PIK3CA Oncogene ∼30% of cases Implicated in resistance to anti-EGFR therapy; involved in PI3K pathway. ( 36 ) BRAF Oncogene ∼10–15% of cases Mutations affect MAPK pathway; associated with aggressive disease. ( 37 ) Open in a new tab Svec, J. et al. stated that the prevalence of SMAD2 and SMAD4 mutations in the cohorts was investigated, with a portion of the cohorts being SMAD2 mutants and a portion of the cohorts being SMAD4 mutants. SMAD4 mutations co-occur with mutations in other signal transduction genes. To comprehend the role of SMAD4 in CRC in an unbiased fashion with respect to candidate genes, a next-generation sequencing-based whole-exome sequencing was conducted. 32 The interaction between transformed MMR-deficient colon epithelium and luminal microorganisms was also investigated, indicating an environmental stress response signaling activation. By incorporation of the findings, SMAD4 functions as a specific gatekeeper tumor suppressor of inflammation-associated CRC. 2.2. Adenomatous Polyposis Coli (APC) Mutations Colorectal cancer (CRC) is a significant public health concern around the globe. Development of CRC has been investigated from the point of view of genetic changes that occur in important cellular pathways, which have resulted in the characterization of CRC-associated mutated genes and proteins. 38 Two major signaling pathways are illustrated in Figure 1 such as Signal 1 representing the TCR-CD3 complex binding to MHC-presented tumor antigens, while Signal 2 shows immune checkpoint CTLA-4 interactions with B7 ligands (CD80/CD86). CTLA-4 binding normally suppresses T-cell activity against cancer cells. A series of studies indicated that mutations in the tumor suppressor gene APC are the initiating event in sporadic colon tumorigenesis. Figure 1. Open in a new tab Key immunological synapse interactions between a T-cell and antigen-presenting cell (APC) in colorectal cancer. Two major signaling pathways are illustrated: Signal 1 represents the TCR-CD3 complex binding to MHC-presented tumor antigens, while Signal 2 shows immune checkpoint CTLA-4 interactions with B7 ligands (CD80/CD86). CTLA-4 binding normally suppresses T-cell activity against cancer cells. This understanding has enabled the development of checkpoint inhibitor, which block CTLA-4 to enhance antitumor immune responses, particularly effective in microsatellite instability-high (MSI-H) colorectal cancers that have higher mutational burdens. APC is a highly conserved and large gene that maps to chromosome 5q21 and has a central function in the regulation of β-catenin and the Wnt signaling pathway. Germline mutations in APC can give rise to familial adenomatous polyposis (FAP), a familial disorder predisposing individuals to the development of numerous colonic adenomatous polyps and subsequent colorectal cancer. 39 It is now widely acknowledged that somatic mutations in APC are the initiating event in approximately 70–80% of sporadic colorectal malignancies. Mutations are reported throughout the length of the gene, although over 80% are located within an 850-bp region of the mutation cluster region corresponding to codons 1286–1513. 40 Downstream mutations in other CRC-associated genes then result in clonal selection and eventual malignant transformation. Recent advances in next-generation sequencing technology have enabled comprehensive genomic investigations to be performed. Whole exome sequencing studies have shown that CRCs can be divided into four subgroups based on the character of their predominant mutations. CRCs with mutations confined to the MCR are classified into the CpG island methylator phenotype (CIMP)-low subgroup. 41 CIMP-high CRCs have mutations at methylated CpG sites throughout the genome targeting genes such as BRAF, MLH1, CACNA1G, and IGFBP7, and lens-epithelial-derived growth factor in particular. CRCs with oncogenic mutations in KRAS are further classified into the CIMP-high/MSI-low subgroup. CRCs with mutations affecting methylation patterns, predominantly in the CIMP-low group, are further classified into the CIMP-high/MSI-high subgroup. 42 Overall, the genome seems to be more stable than previously believed, with geographical segregation of mutations preventing mechanisms or second strikes in cancer-promoting genes that amplify the effect of the first mutation. 2.3. KRAS (Kirsten Rat Sarcoma Viral Oncogene Homologue) and BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) Mutations One of the hallmarks of cancer cells is their ability to become immortal and to proliferate indefinitely. There are several pathways responsible for control of proliferation and cell demise. One of the most essential pathways is the MAPK pathway. It is involved in the transmission of extracellular signals to the cell’s interior, where they activate transcription factors and therefore control cell cycle progression and apoptosis. 43 The initiator of this pathway is an integral plasma membrane protein called RAS, which, among other mutations, is implicated in carcinogenesis. The RAS protein is the emissary between a cell’s surface and the extracellular ligand that the cell receives. In the accompanying figure, the activation processes of all three RAS proteins is demonstrated. After their activation, they form a complex with cytoplasmic RAF. 44 In some forms of colon adenocarcinoma, the active ligand of this complex is the V600E mutant protein of the BRAF gene. Such a complex then reaches the protein MEK, a kinase. MEK phosphorylates and initiates the activation of a gene that has a function in cell proliferation and apoptosis. If there are any mutations in the pathway that constitutively activate those genes, the cancer tumor would use it to continuously proliferate. 45 That is why there are malignant tumors that, if mutation profiles of RAS and BRAF genes are examined, could be classified with regard to the type of tumor. 2.4. TP53 (Tumor Protein P53) Mutations The TP53 gene performs the main function in maintaining the cells’ integrity without any cancer transformation. This gene is responsible for genomic stability in a direct manner, and indirectly by inducing cell cycle arrest, apoptosis, or senescence, in response to DNA damage or genomic instability through regulation of downstream genes, including ribonucleotide reductase RRM2, GADD, HIC, etc. 46 Supervision of cell cycle progression and effective transcriptional regulation during DNA replication have been shown as TP53’s main roles. Approximately 50% of human malignancies have mutations of this gene, and this has been named the most prevalent genetic alteration in colorectal cancer development. The preponderance of TP53 mutations is inactivating and occurs in the genomic region between exons 5 and 9. These are associated with a dearth of TP53 protein expression. 47 The TP53 mutation has been detected at an early stage of colorectal cancer progression, and it is the most prevalent genetic alteration in colorectal malignancies. Therefore, the determination of TP53 mutations is very essential for the early detection of colorectal cancer progression and for the plasma monitoring of colorectal cancer patients. Moreover, the effect of adjuvant therapy on TP53 mutations may be one of the causes for the varied sensitivity among colorectal cancer patients to treatment with long-term exposure to adjuvant radiotherapy and/or chemotherapy. 48 Although the significance of TP53 mutations in colorectal cancer development has been much discussed, the actual influence of these mutations on the prognosis of colorectal cancer patients is not evident with evidence. 49 2.5. PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha) Mutations Elderly patients with colorectal cancer (CRC) face distinct challenges. While older patients are more susceptible to severe postoperative complications, there is no consensus that age itself influences survival outcomes. The prognosis for older patients is influenced by several factors, including the stage of diagnosis, tumor location, pre-existing comorbidities, and type of treatment received. A study on T4 CRC in older patients found that although older patients experienced more postoperative complications, age did not impact relative survival after adjustment for confounding factors. Older patients often have multiple comorbidities and may receive less aggressive treatment due to concerns about tolerability, which can affect their overall management and outcomes. Therefore, age alone should not be a determining factor in denying surgery to elderly patients with CRC. 50 ( 51 ) The introduction of next-generation sequencing and mass spectrometry-based approaches is altering the landscape for therapeutic targeting and biomarker discovery in CRC. PI3K (encoded by PIK3CA) initiates a signaling cascade. Illustrated in the Figure 2 which leads to AKT activation through phosphorylation, which then triggers mTOR, FOXO, and BAD pathways. Figure 2. Open in a new tab Diagram showing the PI3K/AKT/mTOR pathway in colorectal cancer (CRC). When growth factors activate cell surface receptors, PI3K (encoded by PIK3CA) initiates a signaling cascade. This leads to AKT activation through phosphorylation, which then triggers the mTOR, FOXO, and BAD pathways. The result is increased cell proliferation, growth, and survival, hallmarks of cancer. PIK3CA mutations occur in 15–20% of CRCs and are important for treatment decisions, particularly regarding EGFR inhibitor therapy and aspirin effectiveness. Understanding this pathway has enabled the development of targeted treatments such as PI3K inhibitors for PIK3CA-mutated CRC patients. The effectiveness of antiepidermal growth factor receptor treatment in patients with metastatic CRC is strictly dependent on the absence of activating mutations in the downstream component of the Ras-RAF signaling pathway. 52 Data mining of genomics data sets revealed that mutation in PIK3CA was a hallmark of resistance to cetuximab treatment. Patients with PIK3CA mutations are likely resistant to anti-EGFR therapy, suggesting that precise targeting of the PIK3K-PTEN pathway may enhance therapy outcomes against further CRC development. Most of the drugs currently used in clinical practice for CRC treatment remain primarily targeted at inhibiting the main pathways of tumor formation. 53 Chemotherapy treatment, when inappropriately used, developed enormous resistance on wild-type pathways. For such reasons, pharmaceuticals acting on tumorigenic pathways downstream of the KRAS mutation (or on the KRAS p.G12C mutant strain) are yet to be clinically developed. In ovarian cancer, the PI3K pathway is frequently upregulated, playing a crucial role in cell survival, chemoresistance, and genomics stability. It is involved in various processes of DNA replication and cell cycle regulation. However, inhibiting the PI3K pathways can lead to genomic instability and cell death by reducing the activity of proteins such as Aurora Kinase B, which are essential for proper cell division. This can result in issues such as chromosomes not being separated correctly during cell division. For further insights into this mechanism and their implications for ovarian cancer treatment, recent research, such as the study by Aliyuda et al., provides valuable information on advances beyond the PARP inhibitor. 54 PI3K class I has been implicated in many human malignancies, including colorectal cancer. In CRC, mutation or amplification of PIK3CA, which encodes p110α, is detected in approximately 30% of cases. The mutation locus of PIK3CA comprises E542 K, E545 K, and H1047R in exons 9 and 20, respectively. H1047R mutation is particularly essential for cancer development because expression of H1047R in epithelium induces dysplastic lesions and CRC in rodents. 55 The PIK3CA mutation is an early event in CRC development in Apc-min mice. Mutated PI3K plays a pivotal role directly in oncogenic transformation and tumorigenesis. 3. Recent Insights into the Molecular Cascades of Colorectal Cancer The pathways that drive colorectal cancer represent a series of inhibitory mutations in growth-repressive signaling pathways or activating mutations in growth-promoting signaling pathways. Protein assay methodologies rely on antigen recognition of protein-specific antibodies or receptors, with the development of methods independent of these types of molecules lacking the success seen by genomics research. 56 The challenge for proteomics is the issue of sequence variation and the essentially unknown prevalence of alternative splice forms. It is crucial to continue research in genomics, characterization of gene expression, sequence variations, and novel genes. 57 The information regarding the subtype of genetic alterations, characteristics, and prognosis are mentioned in Table 4 . This information considerably aids the analysis of protein expression studies, and a key in membrane protein analysis becomes the construction, validation, and application of a set of specific antibodies directed against all coding genes. Table 4. Overview of Molecular Pathways in the CRC. Subtype Key Genetic Alterations Characteristics Prognosis References CIN (Chromosomal Instability) APC, KRAS, TP53 mutations Characterized by aneuploidy and chromosomal changes. Generally poor prognosis. ( 58 ) MSI-H (Microsatellite Instability-High) MLH1, MSH2, MSH6 mutations High mutation burden; often associated with Lynch syndrome. Better prognosis; responsive to immunotherapy. ( 59 ) CIMP (CpG Island Methylator Phenotype) BRAF mutations and hypermethylation of tumor suppressor genes Characterized by extensive promoter methylation. Variable prognosis; often aggressive. ( 60 ) MSS (Microsatellite Stable) Rarely shows significant mutations in key genes More stable genomic profile; typical in sporadic cases. Intermediate prognosis; varies based on other factors. ( 61 ) Open in a new tab The advance of the proteomics field facilitates the assessment of specific functional states of a given pathway, known cancer-related genes within a specific pathway, novel relationships within the pathway, and novel differentially expressed proteins within a given pathway. Several proteins were identified as potential diagnostic and prognostic markers for colorectal cancer. 62 We recapitulate the role of proteomics and genomics in the study of colorectal cancer and aim to provide new ideas for in-depth research on colorectal cancer. Furthermore, certain proteins were investigated in colorectal cancer biopsies with IHC for their overexpression profiles. Based on their defined functions, the altered proteins could regulate cell growth or death, cell surface proteins, and intracellular proteins as the downstream targets of some representative signal mediators. 63 The Venn diagram ( Figure 3 ) related to the recent insights into the Molecular cascades of colorectal cancer explains the percentage of instability. Collectively, the members of the proteins we identified could work together to maintain colon cell homeostasis by the associated cellular biological pathways, notably in cell differentiation, interaction with the environment, and proliferation. Figure 3. Open in a new tab Three fundamental molecular pathways in colon cancer development: Chromosomal Instability (CIN) occurs in ∼75% of sporadic colon cancers, featuring mutations in APC and p53 genes, typically indicating poorer prognosis. Microsatellite Instability (MSI), present in ∼15% of cases, results from defective DNA mismatch repair and responds well to immunotherapy drugs like pembrolizumab. CpG Island Methylator Phenotype (CIMP) involves epigenetic silencing of tumor suppressor genes through DNA methylation, often associated with BRAF mutations. The overlapping patterns (MSS CIMP+/CIN+ 85%, MSI CIMP+/CIN– 15%, and MSI CIMP–/CIN– 5%) guide personalized treatment strategies, particularly in selecting immunotherapy for MSI-high tumors and targeted therapies for specific molecular subtypes. 3.1. Chromosomal Instability (CIN) Pathway Most colorectal cancers manifest some form of extensive chromosomal instability. Loss of function induced by pathways is an effective mechanism for predisposing to chromosome nondisjunction and aneuploidy development. 64 The alteration of Aurora A kinase that phospho-activates CENP-A, Drosophila INCENP, and Surviving, which is exclusively associated with senescence and cell division defects. CENP-A is a protein necessary to attach the heterochromatin to the centromere and is responsible for correctly assembling the heterochromatin surrounding the centromere. Inhibiting the activity of Aurora A kinase is associated with chromatin condensation and with normal disintegration of the mitotic spindle. Aurora A is upregulated in several human malignancies, including colon cancer. 65 CENP-A is overexpressed in a number of human malignancies and is associated with high levels of drug resistance toward both anticancer agents and a number of other chemicals. Surviving and CENP-A were shown to be necessary for the survival of tumor cell survival. Surprisingly, the latter revealed that although kinetochore abnormalities can contribute to lagging chromosomes, they are not a critical factor in aneuploid formation. 66 Issues such as loss of gene function help prevent premature onset of anaphase by stabilizing microtubule-spindle integration, becoming a stability factor constrained by a 180-base-pair DNA sequence that is required for both centromeric-specific histone binding to the CENP-A chaperone. 3.2. Microsatellite Instability (MSI) Pathway Regarding Microsatellite Instability (MSI), it is noteworthy that PD-L1 expression is significantly higher in cancer with deficient mismatch repair (MMR), particularly those with high MSI (MSI-H), which is often observed in colorectal cancer (CRC). This higher PD-L1 expression makes MSI-H tumors more responsive to anti-PD-1/PD-L1 therapies, which can be crucial for treatment decisions. Immunohistochemistry (IHC) and MSI testing are more commonly used to detect MMR defects. However, these tests can sometimes yield inconsistent results due to differences in mutations affecting IHC outcomes. For instance, IHC may not always accurately reflect the presence of germline mutations if additional somatic mutations exist. Understanding these challenges is essential for accurate diagnosis and treatment planning, as highlighted in studies like the one adeleke et al. which provide insights into the complexities of MSI testing in colorectal cancer patients with lynch syndrome. 67 The most intriguing aspect of MSI is the remarkable associated elevation of T-cell and inflammation markers, which is a potent predictor of sensitivity to checkpoint inhibitor blockade therapy. 68 The molecular pathway of hypermutation contrasts with microsatellite instability seen in the clinical setting of Lynch syndrome. Hypermutated colorectal tumors have specific characteristics and represent a richer source of human T-cell antigens than other colorectal malignancies. 69 Studies based on transcriptome analysis provided evidence that hypermutated colorectal cancers are powerfully immunogenic, lack effective T-cell-mediated immunosurveillance, and manifest hallmarks of immune escape. Genetic patterns in MSI Studies have evaluated somatic driver mutations in MSI-H colorectal cancer, revealing that RNF43, ZNRF3, ACVR2A, SOX9, AMER1, VTI1A, CHD1, RNF183, RPS20, and SCNN1A are the most frequently altered genes. The most mutated gene demonstrates the high number of mutations in an individual colorectal tumor. 70 This mutation distribution reflects fundamental biological selection processes operating within a tumor due to the accumulation of a higher number of mutational signatures. Highly recurrent driver genes are APC, TP53, KRAS, and PIK3CA. Similar numbers of KEGG pathways are seen by deep analysis across the mutational burden in an age-independent manner originating from patients either with microsatellite instability or POLE proofreading deficiency. 71 The genes were upregulated in MSI colorectal malignancies from the p53 pathway, DNA repair, WNT, and others. 3.3. CpG Island Methylator Phenotype (CIMP) Pathway A DNA hypermethylation process of CpG islands of genes is known as CIMP, which gives birth to gene silencing because a methylated gene promoter will not be recognized by the gene transcription factor. There are two separate subtypes of CIMP, CIMP-high and CIMP-low, that distinguish malignancies into two distinct biological and clinical categories. Late-CIMP occurrence of CRC appears for sessile serrated adenomas and is regarded a distinct method of evolving for colon tumors. 72 The CIMP-high pathway involves the silencing of genes crucial for chromosomal stability, with some of them being tumor suppressor genes, DNA repair genes, and cell cycle regulators, while CIMP-low is predominantly associated with p53 signaling and epigenome pathway modification. Such modifications occur on the BRM gene, which is responsible for chromatin remodeling on chromosomal sites that consist of seven hundred genes. Aside from this gene, the remaining genes are all connected to the Wnt signaling pathway and can be among the genes that influence stimulating cell differentiation toward colon cells. 73 Hypermethylation occurring at the CpG islands of these other promoter genes will also be associated with the various molecular features of these cells. When combining both gene silencing events occurring inside the CIMP-high and CIMP-low growth, one can achieve an intestinal stem cell containing molecular signature that can help clinicians predict the response to colon treatment methods based on the epigenetic CIMP growth that occurred. 74 The combination between the CIMP methylation signature and the molecular signature for markers inside the colon stem cell is known as the Stem-like molecular subtype and has been associated with poor overall survival. 75 4. Epigenetic Changes Epigenetic alterations refer to a covalent modification of DNA or its associated proteins, distinct from DNA sequence alteration, that can regulate gene expression. The central role of early state identification and interpretation of the functions of epigenetic alterations encourages the development of alternative techniques. The specific features of mapping experiments rely on the recognition of specific cellular machinery. 76 For example, some methodologies use properties of alpha/beta-theta found in MeDIP and contribute to improved coverage. Nearly all methods for the detection of area methylation include bisulfite conversion, which is the most prevalent technique. Combined with second-generation sequencers and mass spectrometry, bisulfite conversion is considered robust and simple to overview as part of protein or nucleic acid statistical methodologies. 77 DNA methylation is condition-dependent; distinct principles apply to different organisms; therefore, no universal steps can be created, but individual basics for pre-mRNA or mRNA can be generalized. Inspired by Deep-Seq, mass spectrometry could be a credible alternative to the count measurement technique employed for the detection of 5mC, but the present one lacks geo-tagging efficacy. Large 3D regions contain steps required to execute novel employment. 78 It is possible to use gene-to-gene acetylation or hypermethylation using YoMAP, one of the few techniques to approach in vivo and direct cis-regulation. Proteomic techniques falter at the detection stage, with advancements in detection providing a stage for proteomic and genomic tissue-derived capability. 79 With a paucity of adjacent tissues, robust and competent methods of mass spectrometric differentiation between cell-free and cell-bound nuclear proteins are limited. DNA methylation alterations DNA methylation is an epigenetic mechanism that, in cancer, frequently modifies the regulation of gene expression through the elimination of the 5′ cytosine attached to a guanine through a phosphate bond. 80 The addition of the methyl group is catalyzed by various enzymes, including the de novo methyltransferases of the family, which predominantly methylate the daughter strand during DNA replication. DNA methylation predominantly functions as an important regulator of fundamental cellular processes and organ systems, such as embryonic development, X chromosome inactivation, and genomic imprinting. 81 Many CpG islands can be found within the promoter regions of about 60% of human protein-coding genes with altered methylation, particularly the hypermethylation of CpG islands, frequently used as markers for malignancy. Unlike genetic mutations, DNA methylation reduces the quantity of the associated gene product rather than directly influences its function directly. The interaction between gene methylation or demethylation and clinical characteristics has fuelled the search for candidate DMC from the extensive list of human genes for every human cancer. 82 The main approach is to analyze the DNA methylation levels of CpGs within groups or panels of selected tumor suppressors using techniques such as selective demethylation PCR, methylation-specific PCR, methylation-specific multiplex ligation-dependent probe amplification, hybrid capture-based laser microdissection microarray, traction-RNaseq, and EpiTYPER. 4.1. Histone Modifications Histones are essential protein molecules. They are the primary protein components of chromatin. The fundamental unit of chromatin is a nucleosome, which consists of DNA spooled around a core formed of two copies of each of the main histones. 27 This regular winding of DNA typically presents a barrier to transcription, which decreases the access of RNA polymerases to gene promoters. Histones can endure several distinct types of post-translational modifications that have a significant impact on gene regulation. 83 Histone modifications are histone post-translational modifications that determine the epigenetic state of chromatin and aid in the recruitment of various other proteins. The characteristic histone modifications affect the chromatin structure and function and modulate gene transcription. DNA-associated proteins serve an extremely essential function in affecting DNA–protein interactions. 84 The alterations in histone post-translational modification, DNA methylation, and other chromatin-related features are characteristic of many diseases including cancer, cardiac disorders, and psychiatric diseases. Histone deacetylase inhibitors are compounds that are used in the treatment of various malignancies. 85 The histone post-translational modification and histone variants and their exchange in the nucleosome have been shown to be associated with transcription, DNA replication, meiosis, and other chromosomal functions. 86 The dysfunction of histone modification is closely related to many diseases. Histone post-translational modification is regulated by a set of proteins that can both add and delete these modifications in the histone code. Analysis of histone modification in biological samples could aid in understanding how histone modification is involved in the generation and development of diseases. It could help identify therapeutic targets and propose novel diagnostic strategies. The changes in chromatin-related proteins are closely related to disease. 87 A variety of proteomics and genomics technologies for the acquisition of a histone post-translational modification code were used. Histone post-translational modification plays a significant role in gene transcription and other chromosomal functions and is closely related to the occurrence and development of a variety of diseases. 88 5. Gene Expression Profiling Gene expression profiling involves the analysis of mRNA (mRNA) transcripts expressed by one or more genes of an organism. This technique helps researchers remark on the similarity of allelic transcripts across diverse conditions in well-studied organism. Nevertheless, characterizing how alleles respond similarly or differently to perturbations requires measurements of allele expression relative to total transcript levels. 89 Gene expression profiling is a key application of genomics technology, with a significant emphasis on the interpretation of large-scale gene expression data. A few distinct approaches are used to facilitate comparisons of overall gene expression patterns between normal and abnormal tissues or conditions. 90 Overall, gene expression profiling is a potent tool for comparing and contrasting large numbers of genes across many experimental conditions and for investigating gene interaction. Distinguished gene expression profiling entails the analysis of the compound level of expression of mRNAs that encode proteins. Microarrays and other high-throughput platforms can be used to design “expressional fingerprints” that can classify organisms or relevant cell types. Such “fingerprints” enable the comparison of the relative scale of expression of different genes that can provide characteristically unique expressional patterns among different organisms. The advent of enormous parallel sequencing technologies has also altered the approach. 91 Alternative methods using the serial analysis of gene expression can now determine transcript levels and transcript populations within any biological system. The choice of a particular method for profiling is determined by factors such as desired throughput, relative sensitivity and specificity, cost per sequence, apparatus purchase and operating costs, available bioinformatics tools, and personnel resources. 92 Traditional approaches depend on a relatively limited number of high-confidence reference genes. 93 The choice of an appropriate reference gene is essential. The same reference gene is generally used for all samples and conditions, since variability can lead to distortions in fold expression, which can drastically alter interpretations and conclusions derived from experiments. Reference genes should ideally have validated stable expression levels in gene expression profiling. 94 Figure 4 depicts the key components, receptors, transcription factors, and inflammatory mediators of M1 macrophages in immune response regulation. Figure 4. Open in a new tab Diagram illustrates the key components and functions of an M1 macrophage, a specialized immune cell that orchestrates inflammatory responses. The cell surface displays crucial receptors (TLR-4, TLR-2, MHC-II, CD80, and CD86) that recognize potential threats. Internal transcription factors (NF-κB, STAT1, STAT3, IRF3) regulate the cell’s defensive programming. Upon activation, the macrophage releases a diverse array of inflammatory mediators, including cytokines (TNF-α, interleukins) and chemokines (CXCL family), driving immune responses against pathogens and tumors. While essential for defense, this inflammatory activity can potentially lead to tissue damage. 5.1. Identification of Molecular Subtypes The role of proteomics and genomics in colorectal cancer treatment. In the introduction, first, the current situation on the treatment of colon adenocarcinoma is presented, and then review the various phases and therapies in colon adenocarcinoma, including diagnosis, prognosis, and response to chemoradiotherapy. 95 Then, the fundamentals of proteomics and genomics, meta-analysis, proteomic and genomic studies, and contents derived, as well as some applications of knowledge derived from proteomic and genomic studies, are shown. 96 The fact that proteomic and genomic technologies have determination as a common goal, along with the growing use of these techniques, urges the need for a better understanding of these two “big omics”. Numerous questions can be asked, and the relationships between the proteome and genome are many and complex; the one proteome–one genome and one proteome–many genomes’ relations are just examples. Knowledge of all of these relationships is of almost significance for making discoveries in the proteome and optimizing the use of these discoveries at the bedside. Figure 5 illustrates M2 macrophages, highlighting their role in tissue repair, anti-inflammatory responses, surface markers, transcription factors, and secretion of healing factors, while also noting their potential tumor-supporting activities. Figure 5. Open in a new tab M2 macrophage represents an immunoregulatory cell type that plays a critical role in tissue repair and anti-inflammatory responses. Unlike its M1 counterpart, it expresses specific surface markers (CD209, Ym1/2, FIZZ1, CD206, and CD163) that define its healing-oriented phenotype. The cell’s nucleus contains transcription factors (STAT3, STAT6, IRF4, KLF4, JMJD3, PPARδ, PPARγ, cMaf, and cMyc) that regulate anti-inflammatory gene expression. M2 macrophages secrete healing-promoting factors like IL-10, TGF-β, various CCL chemokines, CXCL13, and VEGF. While essential for tissue repair and regeneration, these cells can potentially support tumor growth through their immunosuppressive and angiogenic activities. The increase in genomic and transcriptomic techniques and decreasing costs make it imperative to move beyond the morphologic commonalities between, for example, carriers of colon adenocarcinoma, and offer state-of-the-art patient management options based on the needs and specifics of everyone’s cancer. 97 The primary subtypes in colon adenocarcinoma were derived from the gene expression microarrays by the first version of classification. Also demonstrate the most recent proposals of molecular classification, including a classification based on genetic markers of progression and clinical outcome. In the fourth part of this paper, we illustrate how the use of each serum or tissue may aid in defining the molecular subtypes. 98 6. Principle of Proteomics in CRC CRC is one of the deadliest malignancies in the world and is the third most diagnosed cancer in men and the second in women. The cellular and molecular processes that lead to colorectal carcinogenesis and the progression of precancerous lesions to established cancers are known but have not been fully elucidated, meaning that concisely discussing the molecular mechanisms involved in carcinogenesis and analyzing new therapeutic targets are topics of great interest. 99 Proteomics is a high-throughput technology that allows the detection, identification, and quantification of the complete set of proteins expressed in an organism at a particular time or under specific conditions, playing an essential role in understanding complex interactions within biological systems. Furthermore, recent proteomic advances have been directed toward the study of human cells, tissues, urine, plasma, and other human biological fluids, guiding the diagnosis, prognosis, and therapy of diverse diseases. 100 Muhammad Nur, A. et al.’s chapter objective is to recapitulate the state of the art of proteomic research in primary CRC, CRC cell lines, plasma, and extracellular vesicles deriving from distinct cell types, concentrating on major proteins that are associated with disease development, progression, and therapy. 101 6.1. Protein Expression Patterns There is substantial evidence that variations in protein expression patterns may be hallmarks of certain diseases. It is only recently, however, that the requisite technologies have become available to analyze variations in protein expression on a genome-wide basis. When these technologies become widely used, they may complement the established technology of genomics and provide a more comprehensive view of disease etiology. 102 It is therefore essential to delineate the underlying methodological framework and evaluate its potential to understand, diagnose, and treat diseases. The purpose of this paper is to introduce this new technology and its applications to the field of colorectal cancer, with a focus on novel proteins that may have promise as disease markers. CRC is globally one of the most frequently diagnosed malignant and metastatic diseases. Worldwide, more than one million new cases are diagnosed every year with increasing annual incidence rates. 103 It is also a primary cause of cancer mortality, responsible for 569,000 fatalities globally every year. Standard treatment consists of surgical resection of malignant polyps or tissue combined with adjuvant radiotherapy and chemotherapy; however, patients with phase IV CRC disease face poor prognosis, with 5-year relative survival rates of roughly 10%. In this context, new tools to accurately and objectively classify CRC patients into distinct prognostic groups are urgently required to assist the selection of appropriate treatment strategies. 104 Proteomics entails the large-scale analysis of proteins within a biological specimen in terms of expression levels, diameters, post-translational modifications, or interaction partners. It is seen as a complement to genomics and transcriptomics, being capable of directly revealing the ultimate effectors of a gene at the molecular level. Tumor tissues from 151 CRC patients were examined using bioinformatic methods and proteomic analysis to evaluate changes in protein expression in a cohort containing all Dukes stage A-D tumors without any exclusion criteria. Changes in protein expression levels with Dukes stage of CRC were identified. 105 Functional annotation and pathway analysis were conducted on the detected proteins, which included regulation of transcription, TGF-beta superfamily signaling pathways, DNA repair, cytoskeletal organization, and catalytic activity. Differentially expressed proteins with higher confidence were screened and are proposed as potential CRC biomarkers. 106 Additionally, a partial proteomic analysis was conducted to detect variations in protein expression levels with Dukes stages A, B, and C/D. This analysis suggested that cytoskeletal proteins are downregulated while nucleotide biosynthesis and repair proteins are upregulated. 107 6.2. Differential Protein Expression in Tumor vs Normal Tissue Personalized proteome analysis is required to differentiate the type of proteins expressed between tumor and control matched normal tissue on a patient-by-patient basis to determine the appropriate targets for each patient. They use antibodies unique to a protein or a post-translationally modified form of a protein to analyze the primary surgical samples from 33 colorectal adenocarcinomas and adjacent normal tissues. 108 Thirteen of these cases had corresponding metastases or lymph node involvement; therefore, a set of three tissue samples (tumor, normal, and metastatic) per case was examined. For eight instances, a normal epithelium was procured from a site at a distance from the tumor. Multiple independent antibodies were used to validate protein expression and post-translational modification alterations. 109 While approximately 2000 unique protein forms were identified in each tissue, the number of modified proteins altered during tumor development was substantially greater than those gene products discovered to be modified in terms of their steady-state levels. This is consistent with the fact that it is the highly regulated post-translational state of proteins that leads to the functional activation of these gene products and, hence, a movement of the tumor cell toward its malignant state. 110 Our novel precision proteomics methodology to determine altered expression or post-translational modification using surgically resected colon cancer cases has yielded a comprehensive protein panel demonstrating the primary altered functional groups. Rather than relying on de novo drug design, which has not translated new drug entities into established treatment regimens during the past 10 years, matched target selection becomes possible by using a chemo proteomic strategy that reliably determines the most upregulated drug targets associated with tumor development within study groups reflecting the relevant patient population. 111 6.3. Identification of Prospective Biomarkers Which employs tumor morphology. Recently, more efforts have been made to discover noninvasive tumor biomarkers. They depict the proteins and metabolites in the body but are not immediately related to the histopathological characteristics of the tumor. 112 Current studies focus on using specific protein concentrations to evaluate tumor cell metastasis and patient prognosis. Candidate biomarkers are identified by examining protein concentrations in the body, which are altered because of a particular condition or state. These alterations are associated with the tumor stage and patient survival prognosis. Colorectal cancer is an essential disease, with potential biomarkers. Blood, urine, saliva, and frozen and fixed primary and metastatic tissue samples are common traditional candidate biomaterial sources. Tumor cells perish in distinct ways, and the dying cells subsequently release tumor proteins and defined specific protease profiles. 113 These released products are recognized by immune surveillance. This review summarizes and evaluates results from recent works to identify the potential functions of DNA, RNA, and proteins in colorectal cancer tissue samples. The most suitable biological samples for further biomarker verification in patient blood or urine are presented. The initial investigation discovered a group of endogenous peptides by mass spectrometry. The fecal occult blood test is also significant for the detection of colorectal cancer. In the second study, they implemented and validated a lateral flow test, which required only a small volume of blood for detecting colorectal cancer-specific serum peptides in men. To confirm colorectal cancer and advanced adenoma research, a specific ELISA was approved. It is well-known as a noninvasive faecal tumor marker test with high analytical sensitivity and specificity. 114 The standard endoscopy-negative and fecal-positive negative combination is used to demonstrate the specificity in a large clinical population. The monoclonal antibodies used for detecting resistance rely on a simple ELISA format, which allows for rapid, large-scale identification. 7. Post-translational Modifications As a genetic disease, cancer is generated through the accumulation of genetic and epigenetic abnormalities. Genomics defines the entirety of the genetic abnormalities found in a given neoplasia, while transcriptomics attempts to characterize the resulting gene expression profile globally. 115 In contrast, proteomics characterizes the actual functional protein complement of a neoplasia. Besides the function transmitted by a protein’s amino acid sequence, most functional modulations are controlled by post-translational modifications crucial in both neoplasia’s and the surrounding stroma. The determination and quantitative description of all PTMs in a neoplasia is the role of PTM proteomics, which includes mass spectrometry-based phosphoproteomics, glycoproteomic, and other PTM analyses of interest. 116 PTM proteomics offers an unbiased method to identify aberrant signaling activities giving rise to neoplastic events, as PTMs define the actual biological effects that proteins exert within a cell. PTM profiles offer an opportunity to observe activating signaling events as well as pattern changes following therapies. 117 While common genotyping or sequencing often concentrates on known genes and their corresponding allelic sequence changes possessing prior knowledge, PTM proteomics may be an explorative tool to identify novel therapeutic targets in familial neoplasias. Whenever a PTM is identified within a protein of direct clinical interest or concern, the same analytical concept may be worth transitioning to a less comprehensive, focused platform like immunoassays. 118 7.1. Phosphorylation Changes in Signaling Pathways Proteins endure phosphorylation in colorectal cancer, leading to an uncontrolled signal transduction cascade, enabling cells to become motile and elude the immune system. This perspective discusses phosphorylation alterations in 25 signaling pathways including significant signaling proteins. 119 Recent studies reveal that protein phosphorylation and dephosphorylation are essential events in signal transduction. Signal mutations have been reported to result in significant alterations in the colon cancer proliferation and progression. This perspective compiled 25 significant signaling protein pathways. 120 A comprehensive summary of colorectal cancer phosphorylation changes in 25 important signaling pathways was presented, which can help researchers design beneficial drug targets. Signal transduction pathways play essential functions in cell growth, survival, and tissue homeostasis. Signal mutations or phosphorylated alterations are critical events in a variety of cellular processes, including changes in cell growth, transformation, apoptosis, cell motility, angiogenesis, invasion, and metastasis. 121 In recent years, various signalosome proteins in the signal transduction networks have been demonstrated to be useful tools for systematic, untargeted, label-free, and quantitative analysis of changes in molecular signaling networks in a diverse and broad series of signaling studies related to a variety of fundamental processes in health and disease. Polypeptide phosphorylation, through protein kinases, is one of the essential events in the signal transduction of molecular signal transduction proteins. 122 Phosphorylation accurately and rapidly regulates various signaling network proteins, leading to changes in cell activity such as signal conduction, localization, interaction of other proteins, stability, and half-life of proteins. 7.2. Glycosylation Alterations Aberrant glycosylation represents a key event in the CRC progression. Protein glycosylation is a complex physiological event involving the synthesis and structuring of glycoproteins, but it often becomes deregulated in cancer. Early in the development of CRC phases, intracellular sugar metabolism is altered, primarily through modifications in glycosyltransferase activity. As CRC progresses, the developing hypoxic microenvironments stimulate the selection of specific N-glycan classes. 123 An alternative hypothesis is that the developing hypoxic tumor microenvironment may actively participate in the selection of cancer lineages that possess the glycosidic branching properties found in advanced adenocarcinomas. 124 From a biosynthetic perspective, oncogenesis in colonic carbohydrates appears to be a sequential process. It was found to commence with a minor structural change for which alterations in the expression of specific genes initiated an important control mechanism. This step facilitated the corresponding structural changes, which were amplified by additional expressions of specific genes. 125 These changes facilitate the last structural adhesion modifications, which possibly resulted in malignancy in the postinitiation stages of tumor development. The described stepwise process could be relevant to the diagnosis and/or treatment of colon carcinomas, as there can be virtually no expression of all genes of the three phases simultaneously in most normal cells. 126 8. Protein–Protein Interactions The PPI is crucial for many cellular functions, including the cell cycle, tumor invasion, metastasis, angiogenesis, resistance to signal transduction inhibitors, resistance to apoptosis, and chemo-radiotherapy. 127 Dynamic protein interaction networks and signaling activities should be considered to decipher the network of PPIs in response to certain stimuli for a reliable comprehension of cell function in response to various agents as well as to design new therapeutic strategies. Data on global cellular PPIs ideally characterize all interactions among proteins encoded in an organism. These data form the premise of the interactome, which is the union of all of an organism’s protein–protein interactions. 128 Interatomic approaches can generate large numbers of diverse categories of data that describe the context in which individual interactions occur. Data on PPIs using ligand and RNA screening to investigate oncogenic pathways might establish a broader platform for studying cancer. The combination of ligand-based AP-MS and genetically perturbed PPIs is a potent method to derive high-confidence cancer-relevant signaling networks. PPIs could be modified through several distinct chemotherapy-portrayed protein inhibitors that affect cancer survival, reinforcing the significance of protein complex integrity in the survival of cancer cell lines in culture. 129 The proteomic landscape substantially differs in human colon carcinoma metastasis, where some tissue-specific patterns arise upon metastatic invasion. Such tissue markers could potentially be used for monitoring colorectal cancer progression, drug formulation, and cancer therapy. Currently, to infer the cure, information is extrapolated from the PPI of the diseased buildup protein data. At the same time, certain overexpressed proteins could also function as PPI-based biomarkers. 130 These prospective biomarkers are readily accessible through noninvasive methods for successful and more practical clinical application. The interactome of the most useful cancer hallmark marker genes provides a further benefit in clarifying colorectal cancer metastasis. 8.1. Alterations in Protein Complexes and Signaling Networks Once an alteration in a protein or protein family has been identified in a given malignancy, research into protein interactions and how they form part of cellular signaling networks is crucial. 131 This information is often used to deorphan newly discovered proteins or arrange sorting of nexins, Rho-GTPases, and their putative effector molecules into signaling sets. In the patient cohort, several new candidate factors were identified by our informatics approach, and these provide leads for an in vitro validation study. RCC might therefore represent a plausible choice of cancer type to choose cell lines for those proteins we predict to be implicated in cancer syndromes. 132 Data were also produced by spectral counts, which are related to the amount of protein present in the sample, to enable variations in the tyrosine-phosphorylated protein status to be inferred. These global data were subjected to protein functional association network analysis to identify changes in specific protein complexes or pathways, allowing us to predict signaling alterations in ontogenetically pertinent protein–protein interactions and cellular pathways implicated. For the colorectal adenoma binary data set, we found enrichment of less paradigm proteins implicated in physical complex gene expression. We found about equal fractions of proteins involved in high-throughput assays for gene expression and gene expression involving three tensors involved in gene expression and interacting proteins, an intensity from solitary proteins. 133 In contrast to the mutation data, for a finding of enrichment of the same complex at the level of double bubble, it increases for a finding of enrichment of complexes involving fibrillarin, clustering around the histone fold, and the rhythmic complexes. Similarly to the qualities, we also found no relation between the intensities of gene expression and of protein–protein binding interactions. In contrast to the colorectal data, we found no extra evidence of enrichment, but a proportional shift of interactions of cancer networks for the lung adenocarcinoma triple bubble data. 134 Both levels of support, including some rare, and evidence against our original hypothesis that mutated proteins binding reversibly to enzymes show more signs of high-throughput gene expression at the protein level. 9. Proteogenomic Although advances in genomic and proteomic technologies are numerous and they have brought benefits in terms of disease understanding and novel candidate biomarkers, genomics and molecular-based diagnoses have not yet provided the anticipated results. The mutation frequency in the tyrosine kinase receptor type A is approximately 10.3%, while mutations in the Kirsten rat sarcoma viral oncogene homologue and SMAD Family Member 4 account for 18.4% and 3.5%, respectively. 135 In addition, the K-RAS signaling pathway serves a critical function in regulating cell proliferation, differentiation, and apoptosis. Mutations in these pathways have been reported at about 40–70% in the molecular testing and evaluation of patients’ tissue samples who suffer from metastatic invasive colorectal cancer. However, implementing epidermal growth factor receptor inhibitors as a therapy has potential hazards when the patient possesses the K-RAS or NRAS mutation, since they may develop resistance; thus, many patients will not receive the inhibitors. In addition, the overall survival is scarcely increased in these patients. 136 However, the absence of a viable treatment strategy in CRC explains why improvement is not observed in the outcomes of the patients. Therefore, we intended to highlight the role of proteogenomic, targeting peptides and proteins in the search for novel therapeutic strategies to provide adequate treatment for the disease, taking the evolutionary profile involving the cancer types into consideration. 137 Several works adopt a holistic approach to protein quantification, aimed at strategies for cancer immunotherapy or its sensitivity or resistance to medical management. Studies contemplate the existence of nonmutated tumor-stimulating antigens or that they are exclusive to normal tissues. 138 9.1. Integration of Genomic and Proteomic Data Advances in high-throughput technologies have enabled scientists to obtain valuable and extensive genomic and proteomic data sets from various physiological and pathological conditions. Initially, many researchers analyzed these data sets independently to elucidate the underlying mechanisms related to various diseases. However, most of the disease-causing mechanisms cannot be disclosed by analyzing only the data sets obtained from a single experimental condition. 139 In contrast, a systematic investigation of the relationship between proteomic and genomic data has resulted in an improved understanding of such mechanisms. Several article have reported that integrating both proteomic and genomic data is essential for understanding biological systems and obtaining comprehensive information about altered pathways, and it can yield more reliable and informative data than analyzing the data sets quantitatively with individual data. 140 Some researchers have investigated the effects of genetic variations on various aspects of gene expression by integrating proteomic and genomic data. These investigations focused predominantly on genome-wide association for identifying new SNPs. Thousands of SNPs have been identified through genetic investigations; however, experimental validation of these associations is expensive and insufficient data have been presented in public databases. 141 Therefore, the number of robust genetic regulatory effects on protein levels is rather limited. Such investigations revealed that genetic variations are ubiquitous and can impact differences in steady-state gene expression, as well as protein levels and modifications. Unlike the genomic regulations of mRNA levels and translation rates, the regulations of protein levels and modifications via genetic basis are scarce. These regulations do not have enrichment for regulatory elements in the 3′-UTRs. 9.2. Correlation of Genetic Alterations with Protein Expression The correlation of genetic alterations to protein expression is another essential concept. Although many proteins are involved in signal transduction pathways and there are several post-translational modifications that can affect protein stability, protein expression is nevertheless critically controlled by mRNA levels. Multiple studies have shown that mRNA levels are a reliable surrogate for protein expression across a wide range of gene expression profiles. 142 Furthermore, mathematical models demonstrate that there is only a faint correlation among mRNA stability, protein synthesis, and half-life. Given that most genomic alterations in colorectal cancer patients are characterized at the DNA level, this lack of a reliable correlation between the mRNAs from mutated genes sometimes renders genomic data less informative than they could be. In addition to direct perturbations, the cell is also able to balance altered expression levels of genes through compensatory regulation—by altering the levels of other genes where analogous biological processes are being affected. 143 Quantitation and comprehension of multiple genes encoding components of common biochemical pathways may enhance our capacity to predict the therapeutic benefits of targeted inhibitors. 10. Basic Concepts and Techniques Over the past few years, the proteomics field has exploded in the scientific community, as mass spectrometry-based techniques have enabled innumerable possible quantifications of protein expression in biological systems, providing a comprehensive view of all the proteins that are present in any cell type. 144 Gene expression levels, transcription factors, and protein–protein interactions are by themselves insufficient to predict changes or cellular phenotypes, as such information does not take into consideration post-transcriptional modifications that occur at the entire protein level. Therefore, the focus of proteomics is the determination of the molecular mechanisms that drive any DNA or RNA profile embedded in a cell rather than detecting the genetic events themselves. However, despite the immense quantity of information derived from gene sequencing or mRNA-based techniques, the most functional genomic features of the cell are ultimately the proteins that are expressed and that mediate their implications. 145 Mass spectrometry is a fundamental technique employed in proteomics. By determining the molecular mass of sample ions, ion-mobility analysis, identity/sequence determination based on peptide ions or on unfragmented proteins, or on ion-fragmentation analysis for protein sequences or post-translational modifications, mass spectrometry is depicted as the best candidate to deliver a complete set of techniques that fulfill the requirements needed in any comparative protein expression analysis. 146 In the development of any particular form of mass spectrometry system, the first question that arises is the interface designed for introducing the sample into the mass spectrometry system. The selection of the finest interface is predominantly determined by the method utilized to separate the protein. 147 The most common separation methods include liquid chromatography, capillary electrophoresis, and liquid-phase separation of protein digests, typically peptide IEF-RP HPLC. As a result, the most frequently used forms of mass spectrometry interfaces are LC/MS, CE/MS, and IEF–LC/LC–MS/MS, as well as LC-MALDI–MS/MS, CE-MALDI–MS/MS, and LC-MALDI–MS/MS systems, respectively. 148 11. Pharmacogenomics and Pharmacoproteomics in Colorectal Cancer Treatment Even though colorectal cancer is among the most extensively studied in the context of the involvement of pharmacoproteomic analysis, we can see a distinct imbalance in the number of targeted drugs from the currently known targets. Selecting the more prominent microarray database, we determined the primary pathways associated with differentially expressed genes. 149 Among the myriads of candidates, we singled out 14 proteins that are included in the general analysis of colorectal cancer and its treatment prognosis, commencing from the expression level and ending with the therapeutic event. Diallylated carbohydrate antigens in the oncogenesis of various human malignancies, including colorectal cancer, has been established. 150 The association of overexpression of ST6GalNAcI with aggressive colorectal cancer tumors, metastasis development, and poor prognosis has recently been reported. Use of pharmacogenomics in the treatment selection of patients with colorectal cancer has recently become effective owing to the introduction of targeted therapies with specific clinical applications and toxicities. Tests are performed on the mutational status of EGFR, RAS, BRAF, EGFR ligands, and BRCA1, which define categories of targeted cancer therapy that affect only tumors that have mutations in these genes or activate their pathways. A reliable predictive biomarker for the chemotherapy response has not been found. 151 The DNA repair system plays a key role in the mechanism of action of several systemic chemotherapy medications and is notably the most effective drug used in colorectal cancer therapy; therefore, we could hypothesize that DNA repair activity has a role in resistance to systemic therapy. Protocols have been developed assessing DNA repair protein expression focusing on mono- and bifunctional DNA repair ligases, homologous recombination proteins, and microtubule-associated protein, polymorphic DNA repair gene products responsible for the DNA damage response. 152 11.1. Principles and Applications CRC is among the leading fatal malignancies worldwide. This disease is closely related to dietary habits and lifestyle, as it originates from the colonic epithelium that has been exposed to dietary-derived xenobiotics over the years. Specific instabilities and proteomic instability are coupled with the individual response of cells and tissues to various environmental factors. 153 Over the past decade, research has made significant progress in elucidating genomics and proteomics in various stages or subtypes of CRC. Principally, the development, clinical properties, and prognosis of CRC, like any other cancer, include the genetic scenarios and protein expression patterns, culminating in the progressive transformation from normal mucosa to primary and metastatic lesions. Owing to the genetic and proteomic alterations during tumor progression, as well as the existence of both genetic and nongenetic differences among tumors in various individuals, personalized cancer medicine has been highly pursued. 154 Specific mutations accumulated in oncogenes or suppressor genes result in the complex deregulation of cellular processes. Indeed, these genetic factors, proteomic networks, and cross-talk among these elements determine the diverse and unpredictable responses of individual cancer patients to the same therapeutic intervention. Evidently, these factors may not be identical within various regions in and among distinct primary tumor samples, from which genetic and epigenetic alterations of the cells are entirely indifferent. 155 Large-scale molecular techniques have provided a comprehensive and precise depiction of the molecular events in CRC, including the mutational landscapes, the expression of miRNA, lncRNA, and proteins, and the post-translational modification profiles of proteins expressed in these tumors. Selective inhibitors of mutant or overexpressed proteins have been tested in clinics and have shown differences in therapeutics, making personalized medicine more achievable. The mutational landscape may also direct therapeutic interventions against other diseases. It is then extraordinarily essential, with the conceivably more complex and subtle therapeutic options and additional cell/tissue-associated risk factors in a particular nongermline tumor, to formulate strategies that facilitate prediction. 156 The large and diverse data now allow us to unravel complex intratumor clonal evolution, formation of metastasis or cancer relapse, and activities of kinase/phosphatase enzymes and their substrates that connect the rewiring signal transductions and altered biological outputs. 11.2. Integration of Pharmacogenomics and Pharmacoproteomics Over the past 20 years, advances in molecular technology have changed our comprehension of the types of molecular alterations that might occur in cells. The comprehension and knowledge of the distribution of pharmaceuticals that occur in various molecular alterations and quality are expressed individually. 157 Furthermore, numerous molecular alterations in a gene, mRNA, and protein levels in pharmaceutical drugs were wished to be revealed. Pharmacoproteomic therapy helps the pharmacoproteomic situation and treatment stages; this type also helps treatment adequacy. Until now, in the case of pharmacogenomics and pharmacoproteomics, details on clinical proteomics analysis of colorectal cancer are not available. But protein-integrating pharmacogenomics and pharmacoproteomics under the possible conditions is awarded. After the molecular alterations become known, the pertinent gene and the tumor proteins whose corruption this gene indicates are identified. 158 Later, the tumor proteins’ genomics and pharmacogenomics are also analyzed, and the data created regarding the pharmacoproteins are termed protein–motor correlations, some of which are not precisely known in this context. 11.3. Clinical Applications The genomics and associated genetic mutations of the important inflammatory colorectal tumor suppressor genes, including p53 and mismatch repair genes, in addition to the use of SNP arrays to stratify high-risk constitutional and sporadic patients, are compatible with testing for new noninvasive biomarkers in colorectal cancer. 159 Novel germline alterations in p53 family genes are crucial for designing novel therapeutic strategies. Proteomic technologies are beginning to play their important roles in colorectal cancer management by discovering new noninvasive fecal and blood tests, monitoring chemoprevention strategies, and observing early indicators of antitumor responses. Serum proteomic assays for colon tumor or polyp presence or absence have the potential to abbreviate the diagnostic odyssey. 160 The implications of proteomics and genomics in colorectal cancer management will aid in decreasing the associated effects and fatalities. The clinical efficacy of early diagnosis of aggressive carcinomas for more precise prognostic scores and for the guidance of adjuvant chemotherapy is vitally essential. 161 Disease and patient monitoring during therapies are critical. Recent cancer mortality rates continue to decline in part because of advancements in cancer discovery using new and existing cancer biomarkers. Classification performance data remains imprecise. 162 The application of proteomic technologies in many domains of colorectal cancer screening and patient management is not novel. However, the impact of these cancer technologies on patient morbidity and mortality is often very low in many indications. Proteomic technologies should collectively help to decrease associated effects and fatalities related to any promoted platform used for colorectal cancer. 11.4. Impact on Drug Development and Repurposing Apart from the new insights into drug resistance offered by omics techniques, genomic and proteomic data can enable drug discovery. Although omics approaches do not garner a substantial amount of attention in large-scale research in colorectal cancer, they have been establishing inroads, with preliminary success. 163 A completely realized role could be to integrate mutation data with drug binding assays to disclose the patient-specific drug sensitivity pattern. The omics role in drug repurposing derives from their potential to identify drug targets, decipher cellular perturbations, and establish a causal association between the molecular actions of an active drug and those of a potential drug. 164 These could also entail the discovery of unforeseen off-target inhibition or activation, and insights that correlate a biological mechanism to a particular drug response associated with nonoptimal treatment outcomes. Thus, anticipated to influence the immediate practice of cancer medicine, encompassing the broader domain of precision oncology, and expediting translational research to a timeline that could yield clinical benefits for patients. 11.5. Emerging Technologies and Future Directions The complex physiological mechanisms in response to pharmaceuticals are still not well understood. Both proteomics and genomics seek to conduct extensive analyses of proteins and genes, respectively. Proteins are the main final effectors of all biosynthetic and catabolic processes, and the translation of genes into proteins is responsible for all endogenous functions. 165 Consequently, the study of proteins, known as proteomics, in a certain tissue or body fluid reflects the genotype, providing information directly germane to all structures and functions. However, the proteomics profile is extremely complex. In the past few years, with advances in the disciplines of protein separation, mass spectrometry, and bioinformatics, the analysis of complex protein mixtures has been developed. Currently, both proteins and peptides can be efficiently identified and aspirated in relatively large quantities. 166 Although drivers have been identified for many cancer types, there are a few mutations that are shared among different cancer types, and other mutations seem to be unique to colorectal cancers, including mutations on tumor suppressor genes such as adenomatous polyposis coli and tumor protein 53, as well as the driver protein kinases such as v- K i -ras2 Kirsten rat sarcoma viral oncogene homologue and v-Raf murine sarcoma viral oncogene homologue B. 167 The presence of such unique mutations favors the notion of targeting these driver genes with chemotherapeutic agents, suggesting that targeting only one or two mutations would offer the highest potential for response. Another approach for anticipating the colorectal cancer patient’s response to chemotherapy is to focus on gene expression levels and characterize distinct subtypes of colorectal malignancies. 168 Other groups have focused on oncometabolite production, lysyl oxidase-like 2-catalyzed collagen modification, and other closely related genes. A variety of other technologies have emerged as well, including single-enzyme kinetics, single cell, tissue sections, immunohistochemical assays, and others. 11.6. Ethical and Economic Considerations The clinician or responsible caregiver has an ethical duty to validate the potential benefit and harm of the intended intervention for each malignancy. However, genomic and proteomic testing is costly and not always available. A risk stratification approach can evaluate patients eligible for particular therapies. Even when treatment recommendations are backed by practice guidelines, the physician has the ethical freedom as a patient advocate to request a high-quality clinical trial-based rationale when faced with recommended regimens that are of a prohibitive cost, or have only a hypothetical chance of efficacy, and the risk of a common serious adverse event. 169 The most convincing function of proteomics is presently protein-based marker detection. This list of sensitive and specific markers will increase over time. Genomic profiling is cost-effective for hereditary and polyposis syndromes and a subset of colorectal malignancies. The clinical and research implications of detectable genetic variation in the general population have not been completely realized. However, the government has made available funding for assessing the potential ethical implications of large-scale genomic data sets and approaches to harmonizing public objectives with individual rights. 170 This involves public and stakeholder participation in the discussion of policy choices in genetics research and is worthy of reinforcement. 12. Biomarkers in Personalized Treatment In personalized cancer treatment, microRNAs (miRNAs) hold significant potential as biomarkers, particularly in assessing how well patients with colorectal cancer respond to an EGFR inhibitor like cetuximab. Certain miRNAs, such as miR-31, have been resistant to these treatments, while others like miR-100 and miR-125b are also implicated in treatment response. Developing a signature of miRNAs can help predict treatment outcomes, allowing for a more personalized approach to treating colorectal cancer. This involves identifying specific miRNA patterns that correlate with treatment success and guiding clinicians in selecting the most effective therapies for individual patients. For further insights into predictive biomarker in colorectal cancer, studies like the one by Boussios et al. provide valuable information, supporting the role of miRNAs in advancing personalized medicine. 171 Since mucosal colon biopsy has limited utility, much has been written concerning the discovery of blood and stool biomarkers that can indicate the presence of a tumor. Blood or stool indicates only the presence of malignancy. Blood and stool also lend themselves to the convenience of point-of-care testing. In colorectal cancer, the sensitivity and specificity of a given blood or stool test to monitor for cancer may be different at various stages. The use of biomarkers in personalized treatment has led both diagnostic and therapeutic research in cancer treatment. 172 The search for tumor-associated antigens and surface antibodies has led to the development of antibody-based therapy in the era of passive tumor immunization. Multicomponent techniques and proprietary algorithms have also been developed that facilitate the analysis, alignment, and sequencing of large numbers of genes expressed at any point in time. These strategies have significantly facilitated the identification of a diverse range of robust protein and peptide mutations. Some of these mutations are seen in numerous neoplasms. 173 These techniques and strategies have also been beneficial in the exploration of cancer vaccine targets. Most investigations to date have been carried out with the expressed tumor products available from examination of the clinical trajectory of patients with active disease. With the unprecedented growth of noniterative sequencing methods that are able to identify novel antigens, it is likely that more reliable candidates will be forthcoming as sequencing-based discoveries will not be limited to those antigens that are known to be expressed. It is therefore feasible that a larger number of targetable antigens will be found as novel antigens will now be identified. 174 The enormous genomic information that has resulted from the discovery of alternative loci as targets should also increase the number of goals. The alternative alleles, in combination with a multitude of potential neoepitope targets, are significant and continue to rise. This is due to the simplicity and consistency of liquid biopsy applications. 175 12.1. Identification and Validation Over the expanding number of proteins with known sequences, the number of proteins identified with no known biological activity has also increased. The greatest challenge is the “reverse problem”, that is, identifying proteins using sequences deduced from various genome initiatives. There are no simple techniques available for identifying proteins with no significant homology to any protein with known biological activity. With the data of the distinct genomes being deciphered, we were able to bring forward the sequences of the proteins within the tumor that are present during tumor diagnosis, progression, invasion, or survival. 176 Different methods can be used for identifying proteins whose contributions to tumor promotion have only faintly been remarked upon. The primary methods, such as growth on solid medium, transformation, binding of an activated receptor on the cell surface, nuclear localization, acquisition of a transcriptional transactivating activity, and so forth, are presently being considered and tested by various groups of researchers. 177 Once identified, the existence of a protein must be validated with several other effective biochemical signature techniques. Initially, the protein overrepresentation in the tumor can be validated by Western blotting, following standard techniques. This similarity suggests that, at the biochemical function, sequence motifs contribute to diagnostic accuracy, except when nuclear localization or transcriptional activity is being analyzed. 177 Proteins are electrofocused on a pH-controlled strip of immobilized pH gradient gel and thereafter transferred to a membrane, using first-dimensional isoelectric focusing/two-dimensional polyacrylamide gel, and the position determined by molecular weights/mobility. Peptides may be sequenced by the analysis of microscopically directed peptide effluents or by laser photodissociation. High-accuracy mass measurements are obtained by using Fourier transform mass spectrometry or mass-to-charge ratios. 13. Targeted Therapies in Colorectal Cancer Targeted therapies in colorectal cancer (CRC) represent a revolutionary approach predominantly propelled by advancements in proteomics and genomics. These disciplines have facilitated the identification of specific molecular targets associated with tumor growth and progression. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted therapies concentrate on cellular mechanisms implicated in cancer growth, offering potentially enhanced efficacy and reduced toxicity. 178 In CRC, genomic profiling has unveiled mutations and genetic alterations that are pivotal in the disease’s pathogenesis. One of the most significant advancements is the identification of mutations in the KRAS gene, which are present in approximately 40% of CRC cases. Understanding the function of KRAS has allowed for more precise therapeutic interventions; for instance, patients with KRAS mutations are resistant to certain inhibitors, necessitating alternative strategies. 179 Similarly, BRAF mutations, though less common, are also critical, dictating the responsiveness to targeted agents such as combination inhibitors that address multiple pathways simultaneously. Proteomics complements genomics by providing insights into the functional protein interactions and signaling pathways active within CRC. 180 This allows for a deeper understanding of how tumors resist treatment and metastasize, paving the way for dual-target approaches that simultaneously disrupt multiple cancer-promoting pathways. Agents targeting the vascular endothelial growth factor (VEGF) inhibit angiogenesis, thereby depriving the tumor of necessary nutrients and oxygen. Such therapies, informed by proteomic insights, exemplify the precision medicine approach, as they are administered based on the presence of specific biomarkers within the tumor environment. 181 Moreover, the integration of proteomic and genomic data facilitates the development of personalized treatment regimens, crucial for addressing the heterogeneity of CRC. As researchers continue to investigate these molecular landscapes, the potential to combine multiple targeted therapies with immunotherapy arises, promising a comprehensive strategy against CRC’s adaptive nature. 182 13.1. Current Landscape and Future Directions The current landscape of treatment in colorectal cancer has swiftly expanded over the past decade with the inclusion of new therapies. Previously, for the metastatic setting, therapies were limited to fluoropyrimidine, which was disease stable for around 6 months, followed by the addition of oxaliplatin to the chemotherapy, which was disease stable for around 9 months, or the addition of irinotecan, which was disease stable for around 10 months. 183 Finally, there was the possibility to maintain systemic therapy after the failure of both lines of treatment, with increasing median survival from 15 to 20 months up to 30 to 35 months. 184 14. Case Studies and Clinical Trials Irvine et al. presented a set of data from a discovery cohort, a set of 407 patients with rectal cancer from five different hospitals, including a discovery and a validation cohort. Patients did not receive radio- or chemotherapy before radical surgery, and tumors were staged according to the seventh edition of the UICC TNM classification. 184 The main objectives of such work were to analyze clinical features, genomic instability, and circulating cell-free DNA in patients with rectal cancer and the predictive value for pCR of different variables. In general, the investigators report that TIL and tumor and stromal eosinophil densities were associated with pCR in LARC treated with nCRT. Moreover, CEA for early recurrent rectal cancer seems to be associated with early recurrence but delayed diagnosis. The presence of mutant cell-free TP53 Kirsten rat sarcoma viral oncogene homologue (KRAS) in the serum at diagnosis was associated with shorter disease-free survival and distant metastases. Li et al. have conducted a study on the proteome profiles in patients with different responses to nCRT to find out potential serological biomarkers for further investigation. 185 They used mass spectrometry to investigate serum samples from rectal cancer patients treated with nCRT. A total of 351 high-confidence proteins were identified in the serum. Of these, 11 including Fibrinogen, Aflibercept, Calcium/Calmodulin Dependent Protein Kinase 2, Ferritin Light Chain, BCL2 Associated X, Apoptosis Regulator, Protein Transport Protein Sec24C, Carcinoembryonic Antigen Related Cell Adhesion Molecule 6, Cell Division Cycle 37, FANCD2/FANCI-associated Nuclease 1, Leucine Aminopeptidase 3, and Mucin 2 were upregulated, and four labels were downregulated in response to nCRT compared to baseline. Such findings revealed potential independent serological biomarkers associated with nCRT response and prognosis that warrant further investigation. 186 The review concludes with recent functional genomics and large-scale genomic analyses revealing distinct and precise clinical classifications and potential therapeutic strategies for LARC. 14.1. Successes and Challenges Over the past few years, numerous colorectal cancer proteomics and genomic studies have managed to associate an ever-increasing quantity of putative biomarkers with the presence of the disease and predict drug responses and other clinical outcomes. However, only a very limited number of these studies reported the ultimate clinical qualification and validation that are essential for such biomarkers to be translated into routine clinical applications. 187 The main reasons for this slow translation into the clinic are generally attributed to the small cohorts employed in each study or the huge costs and time-consuming qualification and validation processes required for a statistically strong clinical qualification of each individual revealed candidate biomarker. To effectively translate the outcomes of these colorectal cancer proteomics and genomics studies into the design and development of new therapies and drugs for the management of this disease or to truly incorporate new diagnostic, prognostic, and predictive tests in the clinical setting, the rapid identification and ultimately the utilized information from reused hidden knowledge present in related data sets could be particularly important. 188 The rapid identification of the current concealed knowledge or the effective exploitation of this knowledge can contribute to faster and safer development of biomedical research, notably offering cheaper alternatives for focused experimental validation of the countless candidates that are being disclosed by powerful, yet time-consuming proteomics and genomics platforms. In the present study, performing a search on the currently available colorectal cancer proteomics and genomics studies in order to disclose their uniqueness or their similarities. 189 The aim was to identify potential patterns, connections, or significant relationships that could be established between the molecular and clinical data sets of similar experiments using different approaches. To increase the diversity of data inputs and hence the potential outcome of our aggregation data-mining method, we used as many diverse sources as feasible to store the collected information. 190 Some of the metadata were collected using well-established databases, either released databases that addressed general information about all types of studies, currently developed databases that provided information about each study, or about the metadata associated with the deposited official data set, while some others could only be collected from each publication or downloaded as Supporting Information from the official Web sites of the scientific journal. 15. Ethical and Regulatory Considerations Ethical and regulatory considerations related to the Human Genome Project and the use of genetic information are becoming increasingly prevalent in biomedicine. The implications include, but are not limited to, issues such as the publication of sequence data before patients or populations are adequately apprised and consent has been obtained, the ownership of the information and its commercial applications, and related social, legal, and ethical problems. 191 The impact of creating genetically modified organisms capable of transferring their new genes both within and out of their gene pool on natural species capable of changing a human genome in germline genetic manipulations, which can be of considerable benefit to future generations, should be taken into account with extreme caution. 192 These and other matters are presently being discussed predominantly by bioethics groups and national and international public genome research institutions and may soon be included in the policy exercised by law. It is also essential to become more involved in these discussions, which are traditionally conducted by bioindustry and geneticist stakeholders around the globe. At the outset of the Human Genome Project, new working standards were devised and signed by the participating leading sequencing centers. The main aim of these principles was to make sequence data available for the public and guarantee a maximal acquisition of new knowledge from this investment. 193 However, in the post-HGP era, new working norms are required. At present, the relevant proposals require the bioprojects to respect the principles established by the guidelines. This decision was taken in order to continue to guarantee that participants in genome-based projects also satisfy the requirement of immediate and open access to data and materials without breaching pertinent privacy protections and ethical considerations in the race to patenting and commercialization. 16. Emerging Technologies and Innovations The significant advancements in omics technologies have provided considerable leads to understanding tumor biology. The continuous genomic characterization of tumors offers the promise of eventually elucidating the fundamental genetic causes of human solid tumors, including CRC. Omics-based approaches, coupled with adequate resources and technology, will facilitate a more comprehensive molecular understanding of CRC. 194 No individual methodology for characterizing the genomic, transcriptomic, epigenomic, and proteomic landscapes of CRC is immaculate, and current approaches have limitations. Improvements in single-cell technologies and multiomics, integrating proteomics, genomics, and transcriptomics to obtain a holistic view of the tumor, will direct the development and ultimately patient-specific responses to inform the treatment. Researchers, clinicians, and industries have stimulated progress in establishing community standards, thereby encouraging greater collaboration between these numerous relevant researchers and clinicians. 195 Incorporating this deep sequencing approach aids in the delineation of cancer mutations, gene expression, and more exome and transcriptome profiling while integrating the proteome of these subtypes and determining the closer relationship between the cancer subtypes and the pathway alterations. A systematic study through omics platforms leads to the uncovering of evidence by casting light on drug sensitivities and resistance trends or pinpointing novel cancer driver mutations due to their acquisition during treatment with a drug. Recent analyses have identified protein mutations in resistance to drugs where they are known to be efficacious over a period, thereby emphasizing the ability of proteome-grade data to illuminate this drug resistance mechanism. 196 17. Conclusions There is a need for quicker development of new diagnostics and treatments due to the significant growth in the number of cancer patients worldwide. Using modern proteomics and genomics technologies, we are enhancing our understanding of the pathology of colorectal cancer. In this context, the development of new methods of treating colorectal cancer by finding new protein markers for the detection of new cancer cells, which could aid in finding a new therapy, is necessary. The omics approach enhances the comprehension of complex biological processes, during both colon carcinogenesis and the development of liver metastases. In this Review, we emphasize the function of proteomics and genomics in colon cancer development, lymph nodes, and liver metastases. Furthermore, we discuss differentially regulated proteins in these various stages of carcinogenesis and how understanding this could aid in the discovery of novel treatment strategies for colorectal cancer. The omics approaches aid in identifying proteins that could be used as potential biomarkers or therapeutic targets. With this lead, we could devise novel cancer drugs to help treat patients with colorectal cancer. Knowledge gained in clinical proteomics and genomics is an important prerequisite to characterize potential novel predictive markers for patient response against new targeted treatment or for the assessment of adverse effects, which should be assessed and monitored in the future. Due to large screening capacity and high functional relevance, the nonbiased genomics approaches are the most pertinent instruments in predictive clinical proteomics. Acknowledgments The authors express gratitude to Dr. R.S. Gaud, Advisor to Chancellor SVKM’s NMIMS Deemed-to-be University, for the outstanding research facilities and unwavering encouragement during this project. Glossary Abbreviations APC Adenomatous Polyposis Coli B7 CD80/CD86 Ligand Family BRAF B-Raf Proto-Oncogene BRCA1 Breast Cancer Gene 1 CAF Cancer-Associated Fibroblast CCL Chemokine (C–C Motif) Ligand CDR Complementarity-Determining Region CE Capillary Electrophoresis CE-MS Capillary Electrophoresis-Mass Spectrometry CIMP CpG Island Methylator Phenotype CIN Chromosomal Instability CPD Cyclobutane Pyrimidine Dimer CRC Colorectal Cancer CSC Cancer Stem Cell CSS Cancer-Specific Survival CTLA-4 Cytotoxic T-Lymphocyte-Associated Protein 4 CXCL Chemokine (C-X-C Motif) Ligand CXCR C-X-C Chemokine Receptor DFS Disease-Free Survival DSS Disease-Specific Survival EGFR Epidermal Growth Factor Receptor ELISA Enzyme-Linked Immunosorbent Assay EMT Epithelial-Mesenchymal Transition ERCC Excision Repair Cross-Complementation Group FAP Familial Adenomatous Polyposis FDA Food and Drug Administration FIZZ1 Found in Inflammatory Zone Protein 1 FOXO Forkhead Box O GADD Growth Arrest and DNA Damage-Inducible Genes HDAC Histone Deacetylase HGP High-Grade PIN HGPIN High-Grade Prostatic Intraepithelial Neoplasia HPLC High-Performance Liquid Chromatography HR Homologous Recombination HSP Heat Shock Protein IHC Immunohistochemistry IL-10 Interleukin-10 IRES Internal Ribosome Entry Site IRF Interferon Regulatory Factor JMJD3 Jumonji Domain-Containing Protein 3 KLF4 Krüppel-Like Factor 4 KRAS Kirsten Rat Sarcoma Viral Oncogene Homologue LC-MS Liquid Chromatography–Mass Spectrometry LGR5 Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 lncRNA Long Non-Coding RNA LNP Lipid Nanoparticle MALDI Matrix-Assisted Laser Desorption/Ionization MAPK Mitogen-Activated Protein Kinase miRNA MicroRNA MMR Mismatch Repair MSI Microsatellite Instability MSI-H Microsatellite Instability-High MSS Microsatellite Stable mTOR Mechanistic Target of Rapamycin NER Nucleotide Excision Repair NF-κB Nuclear Factor Kappa B NGS Next-Generation Sequencing NHEJ Non-Homologous End Joining OS Overall Survival PARP Poly(ADP-Ribose) Polymerase PCR Polymerase Chain Reaction PD-1 Programmed Death-1 PDX Patient-Derived Xenograft PI3K Phosphatidylinositol-3-Kinase PPAR Peroxisome Proliferator-Activated Receptor PTEN Phosphatase and Tensin Homologue PTM Post-Translational Modification RRM2 Ribonucleotide Reductase Regulatory Subunit M2 RT Radiation Therapy RTK Receptor Tyrosine Kinase RT-PCR Reverse Transcription Polymerase Chain Reaction SELEX Systematic Evolution of Ligands by Exponential Enrichment SIRT Sirtuin SMAD Sma and Mad Related Family SNP Single Nucleotide Polymorphism STAT Signal Transducer and Activator of Transcription TAM Tumor-Associated Macrophage TCR T-Cell Receptor TGF-β Transforming Growth Factor Beta TIL Tumor-Infiltrating Lymphocytes TME Tumor Microenvironment TNF-α Tumor Necrosis Factor Alpha TP53 Tumor Protein P53 UTR Untranslated Region VEGF Vascular Endothelial Growth Factor Wnt Wingless/Integrated Ym1/2 Chitinase-Like Proteins 1/2 Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article references. Author Contributions Gaurav Paraskar, the first author, drafted the manuscript, conducted material preparation, and performed data collection and analysis. Sankha Bhattacharya and Anitha Kuttiappan, the second and third authors, respectively contributed to the study’s conception and design, writing, editing, supervising. Sankha Bhattacharya and Anitha Kuttiappan reviewed and approved the final manuscript. The authors declare no conflict of interest, and all are responsible for the paper’s content and writing. The authors received no funding for this work. The authors declare no competing financial interest. References Rassy E.; Parent P.; Lefort F.; Boussios S.; Baciarello G.; Pavlidis N. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. Critical Reviews in Oncology/Hematology 2020, 147, 102882 10.1016/j.critrevonc.2020.102882. [ DOI ] [ PubMed ] [ Google Scholar ] Ma L.; Guo H.; Zhao Y.; Liu Z.; Wang C.; Bu J.; Sun T.; Wei J. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduction and Targeted Therapy 2024, 9 (1), 336. 10.1038/s41392-024-02021-w. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Li Y.; Wang B.; Ma F.; Jiang D.; Wang Y.; Li K.; Tan S.; Feng J.; Wang Y.; Qin Z.; et al. Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies. Cell Reports Medicine 2023, 4 (12), 101311 10.1016/j.xcrm.2023.101311. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Zhu H.; Li Y.; Guo J.; Feng S.; Ge H.; Gu C.; Wang M.; Nie R.; Li N.; Wang Y.; et al. Integrated proteomic and phosphoproteomic analysis for characterization of colorectal cancer. Journal of Proteomics 2023, 274, 104808 10.1016/j.jprot.2022.104808. [ DOI ] [ PubMed ] [ Google Scholar ] Adefemi K.; Knight J. C.; Zhu Y.; Wang P. P. Evaluation of population-based screening programs on colorectal cancer screening uptake and predictors in Atlantic Canada: insights from a repeated cross-sectional study. BMC Global and Public Health 2024, 2 (1), 28. 10.1186/s44263-024-00061-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Yildirim O. S.; Yildiz P.; Karaer A.; Calleja-Agius J.; Ozcan S. Exploring the protein signature of endometrial cancer: A comprehensive review through diverse samples and mass spectrometry-based proteomics. European Journal of Surgical Oncology 2024, 108783 10.1016/j.ejso.2024.108783. [ DOI ] [ PubMed ] [ Google Scholar ] Jithesh P. V.; Abuhaliqa M.; Syed N.; Ahmed I.; El Anbari M.; Bastaki K.; Sherif S.; Umlai U.-K.; Jan Z.; Gandhi G.; et al. A population study of clinically actionable genetic variation affecting drug response from the Middle East. npj Genomic Medicine 2022, 7 (1), 10. 10.1038/s41525-022-00281-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Urbiola-Salvador V.; Miroszewska D.; Jabłońska A.; Qureshi T.; Chen Z. Proteomics approaches to characterize the immune responses in cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2022, 1869 (8), 119266 10.1016/j.bbamcr.2022.119266. [ DOI ] [ PubMed ] [ Google Scholar ] He S.-J.; Li J.; Zhou J.-C.; Yang Z.-Y.; Liu X.; Ge Y.-W. Chemical proteomics accelerates the target discovery of natural products. Biochem. Pharmacol. 2024, 230, 116609 10.1016/j.bcp.2024.116609. [ DOI ] [ PubMed ] [ Google Scholar ] Hong Z.; Wang T.; Wang W.; Jing H.; Tang H.; Xu M.; Pan C.; Mu X.; Zhang D.; Gao G.; et al. Proteomic Profiling and Tumor Microenvironment Characterization Reveal Molecular and Immunological Hallmarks of Left-Sided and Right-Sided Colon Cancer Tumorigenesis. J. Proteome Res. 2023, 22 (9), 2973–2984. 10.1021/acs.jproteome.3c00302. [ DOI ] [ PubMed ] [ Google Scholar ] Hofman D. A.; Prensner J. R.; van Heesch S. Microproteins in cancer: identification, biological functions, and clinical implications. Trends Genet. 2025, 41, 146. 10.1016/j.tig.2024.09.002. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Qi L.; Zhu J.; Cheng Z.; Yuan Z.; Qi W.; Wu J.; Qin Y.; Yang J.; Luo T.; Wang M.; et al. Integrated global proteomic and phosphoproteomic analysis of cisplatin-induced apoptosis in A549 cells. Biochem. Biophys. Res. Commun. 2024, 735, 150846 10.1016/j.bbrc.2024.150846. [ DOI ] [ PubMed ] [ Google Scholar ] Tang Z.; Gu Y.; Shi Z.; Min L.; Zhang Z.; Zhou P.; Luo R.; Wang Y.; Cui Y.; Sun Y.; et al. Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. Cell Reports Medicine 2023, 4 (2), 100931 10.1016/j.xcrm.2023.100931. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Zhuang H.; Chen Y. Integrated bioinformatics analysis and validation identify KIR2DL4 as a novel biomarker for predicting chemotherapy resistance and prognosis in colorectal cancer. Heliyon 2024, 10 (18), e37896 10.1016/j.heliyon.2024.e37896. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Zhu H.; Zhang L.; Kou F.; Zhao J.; Lei J.; He J. Targeted therapeutic effects of oral magnetically driven pectin nanoparticles containing chlorogenic acid on colon cancer. Particuology 2024, 84, 53–59. 10.1016/j.partic.2023.02.021. [ DOI ] [ Google Scholar ] Feng S.; Li S.; Wu Z.; Li Y.; Wu T.; Zhou Z.; Liu X.; Chen J.; Fu S.; Wang Z.; et al. Saffron improves the efficacy of immunotherapy for colorectal cancer through the IL-17 signaling pathway. Journal of Ethnopharmacology 2025, 337, 118854 10.1016/j.jep.2024.118854. [ DOI ] [ PubMed ] [ Google Scholar ] Jia L.; Meng Q.; Xu X. Autophagy-related miRNAs, exosomal miRNAs, and circRNAs in tumor progression and drug-and radiation resistance in colorectal cancer. Pathology - Research and Practice 2024, 263, 155597 10.1016/j.prp.2024.155597. [ DOI ] [ PubMed ] [ Google Scholar ] Taylor J. C.; Burke D.; Iversen L. H.; Birch R. J.; Finan P. J.; Iles M. M.; Quirke P.; Morris E. J. A. Minimally Invasive Surgery for Colorectal Cancer: Benchmarking Uptake for a Regional Improvement Programme. Clin. Colorectal Cancer 2024, 23, 382. 10.1016/j.clcc.2024.05.013. [ DOI ] [ PubMed ] [ Google Scholar ] Yang L.-P.; Jiang T.-J.; He M.-M.; Ling Y.-H.; Wang Z.-X.; Wu H.-X.; Zhang Z.; Xu R.-H.; Wang F.; Yuan S.-Q.; et al. Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome. Cell Reports Medicine 2023, 4 (10), 101222 10.1016/j.xcrm.2023.101222. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Bolton H. Genomics and hereditary cancer syndromes in women’s health: a focus on gynaecological management. Obstetrics, Gynaecology & Reproductive Medicine 2024, 34 (10), 271–277. 10.1016/j.ogrm.2024.07.002. [ DOI ] [ Google Scholar ] Roumeliotis T. I.; Williams S. P.; Gonçalves E.; Alsinet C.; Del Castillo Velasco-Herrera M.; Aben N.; Ghavidel F. Z.; Michaut M.; Schubert M.; Price S.; et al. Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. Cell Reports 2017, 20 (9), 2201–2214. 10.1016/j.celrep.2017.08.010. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Yao Z.; Liu T.; Wang J.; Fu Y.; Zhao J.; Wang X.; Li Y.; Yang X.; He Z. Targeted delivery systems of siRNA based on ionizable lipid nanoparticles and cationic polymer vectors. Biotechnology Advances 2025, 81, 108546 10.1016/j.biotechadv.2025.108546. [ DOI ] [ PubMed ] [ Google Scholar ] Saha S.; Ghosh S.; Ghosh S.; Nandi S.; Nayak A. Unraveling the complexities of colorectal cancer and its promising therapies – An updated review. International Immunopharmacology 2024, 143, 113325 10.1016/j.intimp.2024.113325. [ DOI ] [ PubMed ] [ Google Scholar ] Ren Z.; Su R.; Liu D.; Wang Q.; Liu S.; Kong D.; Qiu Y. Yes-associated protein indispensably mediates hirsutine-induced inhibition on cell growth and Wnt/β-catenin signaling in colorectal cancer. Phytomedicine 2024, 135, 156156 10.1016/j.phymed.2024.156156. [ DOI ] [ PubMed ] [ Google Scholar ] Wu T.; Yu Y.; Tu X.; Ye L.; Wang J.; Xie C.; Kuang K.; Yu Y.; Zhuge W.; Wang Z.; et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. Journal of Ethnopharmacology 2025, 336, 118754 10.1016/j.jep.2024.118754. [ DOI ] [ PubMed ] [ Google Scholar ] Chu J.; Yuan C.; Zhou L.; Zhao Y.; Wu X.; Yan Y.; Liu Y.; Liu X.; Jing L.; Dong T.; et al. JianPiTongLuo (JPTL) Recipe regulates anti-apoptosis and cell proliferation in colorectal cancer through the PI3K/AKT signaling pathway. Heliyon 2024, 10 (15), e35490 10.1016/j.heliyon.2024.e35490. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Tian X.; Liu G.; Ji L.; Shen Y.; Gu J.; Wang L.; Ma J.; Xia Z.; Li X. Histone-acetyl epigenome regulates TGF-β pathway-associated chemoresistance in colorectal cancer. Translational Oncology 2025, 51, 102166 10.1016/j.tranon.2024.102166. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Darmadi D.; Aminov Z.; Hjazi A.; R R.; Kazmi S. W.; Mustafa Y. F.; Hosseen B.; Sharma A.; Alubiady M. H. S.; Al-Abdeen S. H. Z. Investigation of the regulation of EGF signaling by miRNAs, delving into the underlying mechanism and signaling pathways in cancer. Exp. Cell Res. 2024, 442 (2), 114267 10.1016/j.yexcr.2024.114267. [ DOI ] [ PubMed ] [ Google Scholar ] Xu Z.; Li W.; Dong X.; Chen Y.; Zhang D.; Wang J.; Zhou L.; He G. Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence. Clin. Chim. Acta 2024, 559, 119686 10.1016/j.cca.2024.119686. [ DOI ] [ PubMed ] [ Google Scholar ] Li M.; Sun X.; Yao H.; Chen W.; Zhang F.; Gao S.; Zou X.; Chen J.; Qiu S.; Wei H.; et al. Genomic methylation variations predict the susceptibility of six chemotherapy related adverse effects and cancer development for Chinese colorectal cancer patients. Toxicol. Appl. Pharmacol. 2021, 427, 115657 10.1016/j.taap.2021.115657. [ DOI ] [ PubMed ] [ Google Scholar ] Casula G.; Lai S.; Loi E.; Moi L.; Zavattari P.; Bonfiglio A. An innovative PCR-free approach for DNA methylation measure: An application for early colorectal cancer detection by means of an organic biosensor. Sens. Actuators, B 2024, 398, 134698 10.1016/j.snb.2023.134698. [ DOI ] [ Google Scholar ] Svec J.; Onhajzer J.; Korinek V. Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist. Critical Reviews in Oncology/Hematology 2024, 204, 104544 10.1016/j.critrevonc.2024.104544. [ DOI ] [ PubMed ] [ Google Scholar ] Liang T.; Luo L.; Xu X.; Du Y.; Yang X.; Xiao J.; Huang X.; Yang H.; Wang S.; Guo L. CDK9 inhibitor elicits APC through a synthetic lethal effect in colorectal cancer cells. Genes & Diseases 2025, 12 (1), 101220 10.1016/j.gendis.2024.101220. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Cai M.; Zhao L.; Qiang Y.; Wang L.; Zhao J. CHNet: A multi-task global–local Collaborative Hybrid Network for KRAS mutation status prediction in colorectal cancer. Artificial Intelligence in Medicine 2024, 155, 102931 10.1016/j.artmed.2024.102931. [ DOI ] [ PubMed ] [ Google Scholar ] Wakayama S.; Ouchi K.; Takahashi S.; Yamada Y.; Komatsu Y.; Shimada K.; Yamaguchi T.; Shirota H.; Takahashi M.; Ishioka C. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2023, 22 (3), 327–338. 10.1016/j.clcc.2023.06.001. [ DOI ] [ PubMed ] [ Google Scholar ] Lim A.; Kang S. Y.; Choi M. K.; Lee M. A.; Kim J. Y.; Koo D. H.; Beom S. H.; Hong S.; Jo J.; Kim Y. H.; et al. 524P A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies. Annals of Oncology 2024, 35, S441. 10.1016/j.annonc.2024.08.593. [ DOI ] [ Google Scholar ] Liu M.; Liu Q.; Hu K.; Dong Y.; Sun X.; Zou Z.; Ji D.; Liu T.; Yu Y. Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment. Critical Reviews in Oncology/Hematology 2024, 204, 104497 10.1016/j.critrevonc.2024.104497. [ DOI ] [ PubMed ] [ Google Scholar ] Aghabozorgi A. S.; Bahreyni A.; Soleimani A.; Bahrami A.; Khazaei M.; Ferns G. A.; Avan A.; Hassanian S. M. Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie 2019, 157, 64–71. 10.1016/j.biochi.2018.11.003. [ DOI ] [ PubMed ] [ Google Scholar ] Wang W.; Zhang L.; Morlock L.; Williams N. S.; Shay J. W.; De Brabander J. K. Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC). J. Med. Chem. 2019, 62 (10), 5217–5241. 10.1021/acs.jmedchem.9b00532. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Narayan S.; Sharma R. Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. Life Sciences 2015, 139, 145–152. 10.1016/j.lfs.2015.08.019. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] DelSignore M.; Jeong T.; Denmark G.; Feldman D.; Shih A.; Zukerberg L.; Chung D. C. Incidence and natural history of gastric high-grade dysplasia in patients with familial adenomatous polyposis syndrome. Gastrointestinal Endoscopy 2023, 97 (1), 25–34. 10.1016/j.gie.2022.09.002. [ DOI ] [ PubMed ] [ Google Scholar ] Tang J.; Lam G. T.; Brooks R. D.; Miles M.; Useckaite Z.; Johnson I. R. D.; Ung B. S. Y.; Martini C.; Karageorgos L.; Hickey S. M.; et al. Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system. Cancer Letters 2024, 585, 216639 10.1016/j.canlet.2024.216639. [ DOI ] [ PubMed ] [ Google Scholar ] Rajendran D.; Oon C. E. Navigating therapeutic prospects by modulating autophagy in colorectal cancer. Life Sciences 2024, 358, 123121 10.1016/j.lfs.2024.123121. [ DOI ] [ PubMed ] [ Google Scholar ] Elrebehy M. A.; Al-Saeed S.; Gamal S.; El-Sayed A.; Ahmed A. A.; Waheed O.; Ismail A.; El-Mahdy H. A.; Sallam A.-A. M.; Doghish A. S. miRNAs as cornerstones in colorectal cancer pathogenesis and resistance to therapy: A spotlight on signaling pathways interplay — A review. Int. J. Biol. Macromol. 2022, 214, 583–600. 10.1016/j.ijbiomac.2022.06.134. [ DOI ] [ PubMed ] [ Google Scholar ] Yang S.; Xia J.; Yang Z.; Xu M.; Li S. Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis. Cancer Treatment and Research Communications 2021, 27, 100311 10.1016/j.ctarc.2021.100311. [ DOI ] [ PubMed ] [ Google Scholar ] Maddah M. M.; Hedayatizadeh-Omran A.; Moosazadeh M.; Alizadeh-Navaei R. Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer 2024, 22 (6), 102226 10.1016/j.clgc.2024.102226. [ DOI ] [ PubMed ] [ Google Scholar ] Di Y.; Jing X.; Hu K.; Wen X.; Ye L.; Zhang X.; Qin J.; Ye J.; Lin R.; Wang Z.; et al. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. Drug Resistance Updates 2023, 66, 100909 10.1016/j.drup.2022.100909. [ DOI ] [ PubMed ] [ Google Scholar ] Wang X.; Yang J.; Yang W.; Sheng H.; Jia B.; Cheng P.; Xu S.; Hong X.; Jiang C.; Yang Y. Multiple roles of p53 in cancer development: Regulation of tumor microenvironment, m6A modification and diverse cell death mechanisms. J. Adv. Res. 2024, 10.1016/j.jare.2024.10.026. [ DOI ] [ PubMed ] [ Google Scholar ] Yamaguchi K.; Nakagawa S.; Saku A.; Isobe Y.; Yamaguchi R.; Sheridan P.; Takane K.; Ikenoue T.; Zhu C.; Miura M.; et al. Bromodomain protein BRD8 regulates cell cycle progression in colorectal cancer cells through a TIP60-independent regulation of the pre-RC complex. iScience 2023, 26 (4), 106563 10.1016/j.isci.2023.106563. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Osseis M.; Nehmeh W. A.; Rassy N.; Derienne J.; Noun R.; Salloum C.; Rassy E.; Boussios S.; Azoulay D. Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes. J. Personalized Med. 2022, 12, 1534. 10.3390/jpm12091534. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Bastos I. M.; Rebelo S.; Silva V. L. M. A comprehensive review on phosphatidylinositol-3-kinase (PI3K) and its inhibitors bearing pyrazole or indazole core for cancer therapy. Chemico-Biological Interactions 2024, 398, 111073 10.1016/j.cbi.2024.111073. [ DOI ] [ PubMed ] [ Google Scholar ] Voutsadakis I. A. The Landscape of PIK3CA Mutations in Colorectal Cancer. Clinical Colorectal Cancer 2021, 20 (3), 201–215. 10.1016/j.clcc.2021.02.003. [ DOI ] [ PubMed ] [ Google Scholar ] Thi Thanh Nguyen N.; Yoon Lee S. Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction. Biochem. Pharmacol. 2024, 224, 116221 10.1016/j.bcp.2024.116221. [ DOI ] [ PubMed ] [ Google Scholar ] Aliyuda F.; Moschetta M.; Ghose A.; Sofia Rallis K.; Sheriff M.; Sanchez E.; Rassy E.; Boussios S. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors. Curr. Cancer Drug Targets 2023, 23 (6), 433–446. 10.2174/1568009623666230209121732. [ DOI ] [ PubMed ] [ Google Scholar ] Denninghoff V.; Muino A.; Diaz M.; Harada L.; Lence A.; Turon P.; Labbrozzi M.; Aguas S.; Peñaloza P.; Avagnina A.; et al. Mutational status of PIK3ca oncogene in oral cancer—In the new age of PI3K inhibitors. Pathology - Research and Practice 2020, 216 (1), 152777 10.1016/j.prp.2019.152777. [ DOI ] [ PubMed ] [ Google Scholar ] Ziyang T.; Xirong H.; Chongming A.; Tingxin L. The potential molecular pathways of Astragaloside-IV in colorectal cancer: A systematic review. Biomedicine & Pharmacotherapy 2023, 167, 115625 10.1016/j.biopha.2023.115625. [ DOI ] [ PubMed ] [ Google Scholar ] Azizan S.; Cheng K. J.; Mejia Mohamed E. H.; Ibrahim K.; Faruqu F. N.; Vellasamy K. M.; Khong T. L.; Syafruddin S. E.; Ibrahim Z. A. Insights into the molecular mechanisms and signalling pathways of epithelial to mesenchymal transition (EMT) in colorectal cancer: A systematic review and bioinformatic analysis of gene expression. Gene 2024, 896, 148057 10.1016/j.gene.2023.148057. [ DOI ] [ PubMed ] [ Google Scholar ] Mühlmeier G. M.; Kraft B.; Wohlfromm T.; Krämer A. 43P Influence of chromosomal instability on cGAS/STING activation and metastatic behavior of lung and colorectal cancer cells. Annals of Oncology 2022, 33, S560. 10.1016/j.annonc.2022.07.070. [ DOI ] [ Google Scholar ] Xiao A.; Li X.; Wang C.; Fakih M. Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer. Clin. Colorectal Cancer 2025, 24, 32. 10.1016/j.clcc.2024.08.001. [ DOI ] [ PubMed ] [ Google Scholar ] Advani S. M.; Swartz M. D.; Loree J.; Davis J. S.; Sarsashek A. M.; Lam M.; Lee M. S.; Bressler J.; Lopez D. S.; Daniel C. R.; et al. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin. Colorectal Cancer 2021, 20 (2), 137–147. 10.1016/j.clcc.2020.09.007. [ DOI ] [ PubMed ] [ Google Scholar ] Bessudo A.; Haseeb A. M.; Reeves J. A.; Zhu X.; Wong L.; Giranda V.; Suttner L.; Liu F.; Chatterjee M.; Sharma S. Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clinical Colorectal Cancer 2024, 23 (3), 285–294. 10.1016/j.clcc.2024.05.003. [ DOI ] [ PubMed ] [ Google Scholar ] Sabouni E.; Nejad M. M.; Mojtabavi S.; Khoshdooz S.; Mojtabavi M.; Nadafzadeh N.; Nikpanjeh N.; Mirzaei S.; Hashemi M.; Aref A. R.; et al. Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways. Biomedicine & Pharmacotherapy 2023, 160, 114395 10.1016/j.biopha.2023.114395. [ DOI ] [ PubMed ] [ Google Scholar ] Al-Mustanjid M.; Mahmud S. M. H.; Royel M. R. I.; Rahman M. H.; Islam T.; Rahman M. R.; Moni M. A. Detection of molecular signatures and pathways shared in inflammatory bowel disease and colorectal cancer: A bioinformatics and systems biology approach. Genomics 2020, 112 (5), 3416–3426. 10.1016/j.ygeno.2020.06.001. [ DOI ] [ PubMed ] [ Google Scholar ] Bhatia S.; Khanna K. K.; Duijf P. H. G. Targeting chromosomal instability and aneuploidy in cancer. Trends Pharmacol. Sci. 2024, 45 (3), 210–224. 10.1016/j.tips.2024.01.009. [ DOI ] [ PubMed ] [ Google Scholar ] Shaikh R.; Bhattacharya S.; Prajapati B. G. Microsatellite instability: A potential game-changer in colorectal cancer diagnosis and treatment. Results in Chemistry 2024, 7, 101461 10.1016/j.rechem.2024.101461. [ DOI ] [ Google Scholar ] Böhly N.; Schmidt A.-K.; Zhang X.; Slusarenko B. O.; Hennecke M.; Kschischo M.; Bastians H. Increased replication origin firing links replication stress to whole chromosomal instability in human cancer. Cell Reports 2022, 41 (11), 111836 10.1016/j.celrep.2022.111836. [ DOI ] [ PubMed ] [ Google Scholar ] Adeleke S.; Haslam A.; Choy A.; Diaz-Cano S.; Galante J. R.; Mikropoulos C.; Boussios S. Microsatellite Instability Testing in Colorectal Patients with Lynch Syndrome: Lessons Learned from a Case Report and How to Avoid Such Pitfalls. Personalized Medicine 2022, 19 (4), 277–286. 10.2217/pme-2021-0128. [ DOI ] [ PubMed ] [ Google Scholar ] Tang E.; Tang C.; Lin X.; Chen Y.; Zhou Y.; Pan C.; Jiang H. Clinical performance of the TrueMark MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort. Gene 2024, 927, 148745 10.1016/j.gene.2024.148745. [ DOI ] [ PubMed ] [ Google Scholar ] Peng L.; Zhang X.; Zhu Y.; Shi L.; Ai K.; Huang G.; Ma W.; Wei Z.; Wang L.; Ma Y. T2WI and ADC radiomics combined with a nomogram based on clinicopathologic features to quantitatively predict microsatellite instability in colorectal cancer. Acad. Radiol. 2025, 32, 1431. 10.1016/j.acra.2024.10.002. [ DOI ] [ PubMed ] [ Google Scholar ] Xu Y.; Liu K.; Li C.; Li M.; Zhou X.; Sun M.; Zhang L.; Wang S.; Liu F.; Xu Y. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms. eBioMedicine 2024, 103, 105142 10.1016/j.ebiom.2024.105142. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Ambrosini M.; Tougeron D.; Modest D.; Guimbaud R.; Kopetz S.; Decraecker M.; Kim S.; Coutzac C.; Perkins G.; Alouani E.; et al. BRAF + EGFR ± MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur. J. Cancer 2024, 210, 114290 10.1016/j.ejca.2024.114290. [ DOI ] [ PubMed ] [ Google Scholar ] Ogino S.; Kawasaki T.; Kirkner G. J.; Kraft P.; Loda M.; Fuchs C. S. Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample. Journal of Molecular Diagnostics 2007, 9 (3), 305–314. 10.2353/jmoldx.2007.060170. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Jover R.; Nguyen T.-P. T.; Pérez-Carbonell L.; Payá A.; Alenda C.; Rojas E.; Castells A.; Andreu M.; Llor X.; Boland C. R.; et al. 745 Colorectal Cancers (CRCs) With the CpG Island Methylator Phenotype (CIMP) Do Not Show Improved Survival With 5-Fluorouracil (5FU)-Based Adjuvant Chemotherapy. Gastroenterology 2010, 138 (5), S-102. 10.1016/S0016-5085(10)60466-0. [ DOI ] [ Google Scholar ] Xicola R. M.; Nguyen T.-P. T.; Doyle B. J.; Bandipalliam P.; Syngal S.; Reyes J.; Cordero C.; Grzybowski J.; Sapoznik V. R.; Grzybowski M. N.; et al. 198 CpG-Island Methylator Phenotype (CIMP) and Alterations in RAS-Raf Signaling in Hereditary Non-Polyposis Colorectal Cancers Without Mismatch Repair Deficiency (MSS HNPCC). Gastroenterology 2009, 136 (5), A-37. 10.1016/S0016-5085(09)60169-4. [ DOI ] [ Google Scholar ] Khalid-de Bakker C.; Jonkers D.; Smits K. M.; Hameeteman W.; de Bruine A. P.; Stockbrügger R.; van Engeland M.; Masclee A. S1964 Higher Prevalence of CpG Island Methylator Phenotype-Positive (CIMP+) Status in Advanced Adenomas Detected Using Colonoscopy for Colorectal Cancer (CRC) Screening. Gastroenterology 2009, 136 (5), A-302. 10.1016/S0016-5085(09)61380-9. [ DOI ] [ Google Scholar ] Ang P. W.; Li W. Q.; Soong R.; Iacopetta B. BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. Cancer Letters 2009, 273 (2), 221–224. 10.1016/j.canlet.2008.08.001. [ DOI ] [ PubMed ] [ Google Scholar ] Porcellini E.; Laprovitera N.; Riefolo M.; Ravaioli M.; Garajova I.; Ferracin M. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters 2018, 419, 84–95. 10.1016/j.canlet.2018.01.049. [ DOI ] [ PubMed ] [ Google Scholar ] Mrazek A.; Porro L.; Carmical J. R.; Gomez G.; Gajjar A.; Hellmich M. R.; Chao C. Genetic and Epigenetic Changes in Carcinoma-Associated Fibroblasts Derived From Human Colorectal Cancers. J. Am. College Surg. 2013, 217 (3), S133. 10.1016/j.jamcollsurg.2013.07.310. [ DOI ] [ Google Scholar ] Rodger E. J.; Gimenez G.; Ajithkumar P.; Stockwell P. A.; Almomani S.; Bowden S. A.; Leichter A. L.; Ahn A.; Pattison S.; McCall J. L.; et al. An epigenetic signature of advanced colorectal cancer metastasis. iScience 2023, 26 (6), 106986 10.1016/j.isci.2023.106986. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Luo M.; Yang X.; Chen H.-N.; Nice E. C.; Huang C. Drug resistance in colorectal cancer: An epigenetic overview. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021, 1876 (2), 188623 10.1016/j.bbcan.2021.188623. [ DOI ] [ PubMed ] [ Google Scholar ] Pandkar M. R.; Shukla S. Epigenetics and alternative splicing in cancer: old enemies, new perspectives. Biochem. J. 2024, 481 (21), 1497–1518. 10.1042/BCJ20240221. [ DOI ] [ PubMed ] [ Google Scholar ] Jin L.; Wu S.; Mao C.; Wang C.; Zhu S.; Zheng Y.; Zhang Y.; Li Z.; Cui Z.; Jiang H.; et al. Rapid and effective treatment of chronic osteomyelitis by conductive network-like MoS2/CNTs through multiple reflection and scattering enhanced synergistic therapy. Bioactive Materials 2024, 31, 284–297. 10.1016/j.bioactmat.2023.08.005. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Tamagawa H.; Oshima T.; Numata M.; Yamamoto N.; Shiozawa M.; Morinaga S.; Nakamura Y.; Yoshihara M.; Sakuma Y.; Kameda Y.; et al. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. European Journal of Surgical Oncology (EJSO) 2013, 39 (6), 655–661. 10.1016/j.ejso.2013.02.023. [ DOI ] [ PubMed ] [ Google Scholar ] Jiang X.; Tan J.; Li J.; Kivimäe S.; Yang X.; Zhuang L.; Lee P. L.; Chan M. T. W.; Stanton L. W.; Liu E. T.; et al. DACT3 Is an Epigenetic Regulator of Wnt/β-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications. Cancer Cell 2008, 13 (6), 529–541. 10.1016/j.ccr.2008.04.019. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Chen J.; Yang T.; Xiao T.; Wang Z.; He F.; Bao T.-t.; Cao Y. Overview and new insights of lysine-specific histone demethylase 1 in colorectal cancer: promoting epithelial-mesenchymal transition and stemness features of cancer stem cells. Oncologie 2024, 26 (3), 369–377. 10.1515/oncologie-2023-0562. [ DOI ] [ Google Scholar ] Wang Q.; Ma C.; Mao H.; Wang J. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates the ZNF334 gene to inhibit the growth of colorectal cancer. Int. J. Biol. Macromol. 2024, 277, 134580 10.1016/j.ijbiomac.2024.134580. [ DOI ] [ PubMed ] [ Google Scholar ] Gao J.; Zhang H.; Liu S.; Guo L.; Zeng X.; Yuan W.; Li T.; He S. HDAC1 promotes basal autophagy and proliferation of colorectal cancer cells by mediating ATG16L1 deacetylation. Biochem. Biophys. Res. Commun. 2024, 735, 150667 10.1016/j.bbrc.2024.150667. [ DOI ] [ PubMed ] [ Google Scholar ] Li H.; Wu J.; Zhang N.; Zheng Q. Transglutaminase 2-mediated histone monoaminylation and its role in cancer. Biosci. Rep. 2024, 10.1042/BSR20240493. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Lin S.; Shen Z.; Yang Y.; Qiu Y.; Wang Y.; Wang X. Expression profiles of radio-resistant genes in colorectal cancer cells. Radiation Medicine and Protection 2021, 2 (2), 48–54. 10.1016/j.radmp.2021.04.006. [ DOI ] [ Google Scholar ] Lopez N. E.; Weiss A. C.; Robles J.; Fanta P.; Ramamoorthy S. L. A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. American Journal of Surgery 2016, 212 (4), 700–714. 10.1016/j.amjsurg.2016.06.019. [ DOI ] [ PubMed ] [ Google Scholar ] Camp E. R.; Gerry B.; Chung D.; Findlay V.; Ford M.; Curran T. Differences in Immune Gene Expression Profiles of Colorectal Cancer Between African-American and European-American Patients. J. Am. College Surg. 2020, 231 (4), S265–S266. 10.1016/j.jamcollsurg.2020.07.581. [ DOI ] [ Google Scholar ] Lee Y.-C.; Lee J.-W.; Huang C.-C.; Wu M.-H.; Lee K.-H. Data supporting the identification of compound for inhibition of survivin of colorectal cancer by using ingenuity pathway analysis of gene expression profiling of colorectal cancer tissues. Data in Brief 2015, 4, 235–238. 10.1016/j.dib.2015.05.017. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Hernandez-Rocha C.; Nayeri S.; Borowski K.; Smith M. I.; Stempak J. M.; Conner J.; Silverberg M. S. Mo1124 RNA-SEQ GENE EXPRESSION PROFILE REVEALS THAT DUOXA2 AND CCL11 GENES ARE ASSOCIATED WITH PROGRESSIVE RISK OF COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS. Gastroenterology 2020, 158 (6), S-796. 10.1016/S0016-5085(20)32665-2. [ DOI ] [ Google Scholar ] Antoniotti C.; Boccaccino A.; Seitz R.; Giordano M.; Rossini D.; Ambrosini M.; Salvatore L.; McGregor K.; Bergamo F.; Conca V.; et al. SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study. Annals of Oncology 2022, 33, S372. 10.1016/j.annonc.2022.04.434. [ DOI ] [ Google Scholar ] Raghav S.; Suri A.; Kumar D.; Aakansha A.; Rathore M.; Roy S. A hierarchical clustering approach for colorectal cancer molecular subtypes identification from gene expression data. Intelligent Medicine 2024, 4 (1), 43–51. 10.1016/j.imed.2023.04.002. [ DOI ] [ Google Scholar ] Yang B.-L.; Cheng C.-C.; Ho A.-S. Sa1696 – Stat3-Mediated Gene and Mirna Expression Profiling Analysis in Colorectal Cancer Cells-Derived Cancer Stem-Like Tumorspheres. Gastroenterology 2019, 156 (6), S-369. 10.1016/S0016-5085(19)37763-7. [ DOI ] [ Google Scholar ] Li M.; Lu M.; Li J.; Gui Q.; Xia Y.; Lu C.; Shu H. Classification of molecular subtypes for colorectal cancer and development of a prognostic model based on necroptosis-related genes. Heliyon 2024, 10 (5), e26781 10.1016/j.heliyon.2024.e26781. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Firouzjaei A. A.; Mahmoudi A.; Almahmeed W.; Teng Y.; Kesharwani P.; Sahebkar A. Identification and analysis of the molecular targets of statins in colorectal cancer. Pathology - Research and Practice 2024, 256, 155258 10.1016/j.prp.2024.155258. [ DOI ] [ PubMed ] [ Google Scholar ] Wang Y.; Zhang L.; Xu J.; Ma J. The Proteomic Landscape of Monocytes in Response to Colorectal Cancer Cells. J. Proteome Res. 2024, 23 (9), 4067–4081. 10.1021/acs.jproteome.4c00400. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Han Y.; Pu Y.; Liu X.; Liu Z.; Chen Y.; Tang L.; Zhou J.; Song Q.; Ji Q. YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m6A-dependent manner. Cancer Letters 2024, 601, 217186 10.1016/j.canlet.2024.217186. [ DOI ] [ PubMed ] [ Google Scholar ] Hatta M. N. A.; Mohamad Hanif E. A.; Chin S.-F.; Low T. Y.; Neoh H.-m. Parvimonas micra infection enhances proliferation, wound healing, and inflammation of a colorectal cancer cell line. Biosci. Rep. 2023, 10.1042/BSR20230609. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Wang Y.; Wu Q.; Liu J.; Wang X.; Xie J.; Fu X.; Li Y. WDR77 in Pan-Cancer: Revealing expression patterns, genetic insights, and functional roles across diverse tumor types, with a spotlight on colorectal cancer. Translational Oncology 2024, 49, 102089 10.1016/j.tranon.2024.102089. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Fan S.; Fleischer J. R.; Dokshokova L.; Böhme L. S.; Haas G.; Schmitt A. M.; Gätje F. B.; Rosen L.-A. E.; Bohnenberger H.; Ghadimi M.; et al. High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern. Molecular Therapy: Oncology 2024, 32 (3), 200828 10.1016/j.omton.2024.200828. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Natarajan S. R.; Krishnamoorthy R.; Alshuniaber M. A.; Al-Anazi K. M.; Farah M. A.; Rajagopal P.; Palanisamy C. P.; Veeraraghavan V. P.; Jayaraman S. Identification of FOXM1 as a novel protein biomarker and therapeutic target for colorectal cancer progression: Evidence from immune infiltration and bioinformatic analyses. Int. J. Biol. Macromol. 2024, 282, 137201 10.1016/j.ijbiomac.2024.137201. [ DOI ] [ PubMed ] [ Google Scholar ] Alotaibi M. A.; Al-Hazani T. M. I.; Alwaili M. A.; Jalal A. S.; Alshaya D. S.; Safhi F. A.; Alamoudi M. O.; Alarifi S.; Saeed Al-Qahtani W. SARS-CoV-2 virus associated angiotensin converting enzyme 2 expression modulation in colorectal cancer: Insights from mRNA and protein analysis COVID-19 associated (ACE2) expression in colorectal cancer. Microbial Pathogenesis 2023, 185, 106389 10.1016/j.micpath.2023.106389. [ DOI ] [ PubMed ] [ Google Scholar ] Zhou M.; Niu H.; Lu D.; Zhang H.; Luo D.; Yu Z.; Huang G.; Li J.; Xiong C.; Tang Q.; et al. Wu Mei Wan suppresses colorectal cancer stemness by regulating Sox9 expression via JAK2/STAT3 pathway. Journal of Ethnopharmacology 2025, 338, 118998 10.1016/j.jep.2024.118998. [ DOI ] [ PubMed ] [ Google Scholar ] Chen B.; Zhou G.; Chen A.; Peng Q.; Huang L.; Liu S.; Huang Y.; Liu X.; Wei S.; Hou Z.-y.; et al. The synchronous upregulation of a specific protein cluster in the blood predicts both colorectal cancer risk and patient immune status. Gene 2024, 930, 148842 10.1016/j.gene.2024.148842. [ DOI ] [ PubMed ] [ Google Scholar ] Liu G.; Hu C.; Wei J.; Li Q.; Zhang J.; Zhang Z.; Qu P.; Cao Z.; Wang R.; Ji G.; et al. The association of appendectomy with prognosis and tumor-associated macrophages in patients with colorectal cancer. iScience 2024, 27 (9), 110578 10.1016/j.isci.2024.110578. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Wan R.; Chen Y.; Feng X.; Luo Z.; Peng Z.; Qi B.; Qin H.; Lin J.; Chen S.; Xu L.; et al. Exercise potentially prevents colorectal cancer liver metastases by suppressing tumor epithelial cell stemness via RPS4X downregulation. Heliyon 2024, 10 (5), e26604 10.1016/j.heliyon.2024.e26604. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Leonard N. A.; Corry S. M.; Reidy E.; Egan H.; O’Malley G.; Thompson K.; McDermott E.; O’Neill A.; Zakaria N.; Egan L. J.; et al. Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling. iScience 2024, 27 (9), 110701 10.1016/j.isci.2024.110701. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Hu S.; Qin J.; Ding M.; Gao R.; Xiao Q.; Lou J.; Chen Y.; Wang S.; Pan Y. Bulk integrated single-cell-spatial transcriptomics reveals the impact of preoperative chemotherapy on cancer-associated fibroblasts and tumor cells in colorectal cancer, and construction of related predictive models using machine learning. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2025, 1871 (1), 167535 10.1016/j.bbadis.2024.167535. [ DOI ] [ PubMed ] [ Google Scholar ] So̷reide K.; Nedrebo̷ B. S.; Knapp J.-C.; Glomsaker T. B.; So̷reide J. A.; Ko̷rner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surg. Oncol. 2009, 18 (1), 31–50. 10.1016/j.suronc.2008.06.006. [ DOI ] [ PubMed ] [ Google Scholar ] Bech J. M.; Terkelsen T.; Bartels A. S.; Coscia F.; Doll S.; Zhao S.; Zhang Z.; Brünner N.; Lindebjerg J.; Madsen G. I.; et al. Proteomic Profiling of Colorectal Adenomas Identifies a Predictive Risk Signature for Development of Metachronous Advanced Colorectal Neoplasia. Gastroenterology 2023, 165 (1), 121–132. 10.1053/j.gastro.2023.03.208. [ DOI ] [ PubMed ] [ Google Scholar ] Beutgen V. M.; Shinkevich V.; Pörschke J.; Meena C.; Steitz A. M.; Pogge von Strandmann E.; Graumann J.; Gómez-Serrano M. Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology. Molecular & Cellular Proteomics 2024, 23 (9), 100830 10.1016/j.mcpro.2024.100830. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Saadi S.; Nacer N. E.; Saari N.; Mohammed A. S.; Anwar F. The underlying mechanism of nuclear and mitochondrial DNA damages in triggering cancer incidences: Insights into proteomic and genomic sciences. J. Biotechnol. 2024, 383, 1–12. 10.1016/j.jbiotec.2024.01.013. [ DOI ] [ PubMed ] [ Google Scholar ] Wong G. Y. M.; Li J.; McKay M.; Castaneda M.; Bhimani N.; Diakos C.; Hugh T. J.; Molloy M. P. Proteogenomic Characterization of Early Intrahepatic Recurrence after Curative-Intent Treatment of Colorectal Liver Metastases. J. Proteome Res. 2024, 23 (10), 4523–4537. 10.1021/acs.jproteome.4c00440. [ DOI ] [ PubMed ] [ Google Scholar ] Reymond M. A.; Steinert R.; Kähne T.; Sagynaliev E.; Allal A. S.; Lippert H. Expression and functional proteomics studies in colorectal cancer. Pathology - Research and Practice 2004, 200 (2), 119–127. 10.1016/j.prp.2004.02.001. [ DOI ] [ PubMed ] [ Google Scholar ] Ma W.; Tang W.; Kwok J. S. L.; Tong A. H. Y.; Lo C. W. S.; Chu A. T. W.; Chung B. H. Y. A review on trends in development and translation of omics signatures in cancer. Computational and Structural Biotechnology Journal 2024, 23, 954–971. 10.1016/j.csbj.2024.01.024. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Luo Y.; Liang G.; Zhang Q.; Luo B. The role of cGAS-STING signaling pathway in colorectal cancer immunotherapy: Mechanism and progress. International Immunopharmacology 2024, 143, 113447 10.1016/j.intimp.2024.113447. [ DOI ] [ PubMed ] [ Google Scholar ] Xie S.-A.; Zhang W.; Du F.; Liu S.; Ning T.-T.; Zhang N.; Zhang S.-T.; Zhu S.-T. PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway. Heliyon 2024, 10 (16), e36017 10.1016/j.heliyon.2024.e36017. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Feng H.; Yang Y.; Chen H.; Zhang Z.; Zeng J.; Huang Y.; Yang X.; Yang L.; Du J.; Cao Z. Jiedu Xiaozheng Yin extract targets cancer stem cells by Wnt signaling pathway in colorectal cancer. Journal of Ethnopharmacology 2025, 337, 118710 10.1016/j.jep.2024.118710. [ DOI ] [ PubMed ] [ Google Scholar ] Lee J.-Y.; Park S.; Park E. J.; Pagire H. S.; Pagire S. H.; Choi B.-W.; Park M.; Fang S.; Ahn J. H.; Oh C.-M. Inhibition of HTR2B-mediated serotonin signaling in colorectal cancer suppresses tumor growth through ERK signaling. Biomedicine & Pharmacotherapy 2024, 179, 117428 10.1016/j.biopha.2024.117428. [ DOI ] [ PubMed ] [ Google Scholar ] Shih P.-C.; Chen H.-P.; Hsu C.-C.; Lin C.-H.; Ko C.-Y.; Hsueh C.-W.; Huang C.-Y.; Chu T.-H.; Wu C.-C.; Ho Y.-C.; et al. Long-term DEHP/MEHP exposure promotes colorectal cancer stemness associated with glycosylation alterations. Environ. Pollut. 2023, 327, 121476 10.1016/j.envpol.2023.121476. [ DOI ] [ PubMed ] [ Google Scholar ] Varadharaj V.; Petersen W.; Batra S. K.; Ponnusamy M. P. Sugar symphony: glycosylation in cancer metabolism and stemness. Trends Cell Biol. 2024, 10.1016/j.tcb.2024.09.006. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Wang D.; Madunić K.; Mayboroda O. A.; Lageveen-Kammeijer G. S. M.; Wuhrer M. (Sialyl)Lewis Antigen Expression on Glycosphingolipids, N-, and O-Glycans in Colorectal Cancer Cell Lines is Linked to a Colon-Like Differentiation Program. Molecular & Cellular Proteomics 2024, 23 (6), 100776 10.1016/j.mcpro.2024.100776. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Rodriguez E.; Lindijer D. V.; van Vliet S. J.; Garcia Vallejo J. J.; van Kooyk Y. The transcriptional landscape of glycosylation-related genes in cancer. iScience 2024, 27 (3), 109037 10.1016/j.isci.2024.109037. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Abduljaleel Z.; Athar M.; Al-Allaf F. A.; Al-Dehlawi S.; Vazquez J. R. Association of functional variants and protein-to-protein physical interactions of human MutY homolog linked with familial adenomatous polyposis and colorectal cancer syndrome. Non-coding RNA Research 2019, 4 (4), 155–173. 10.1016/j.ncrna.2019.11.005. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Wang L.; Jiang J.; Zhang L.; Zhang Q.; Zhou J.; Li L.; Xu X.; You Q. Discovery and Optimization of Small Molecules Targeting the Protein–Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. J. Med. Chem. 2020, 63 (3), 1281–1297. 10.1021/acs.jmedchem.9b01659. [ DOI ] [ PubMed ] [ Google Scholar ] Dong X.; Zhang K.; Yi S.; Wang L.; Wang X.; Li M.; Liang S.; Wang Y.; Zeng Y. Multi-omics profiling combined with molecular docking reveals immune-inflammatory proteins as potential drug targets in colorectal cancer. Biochem. Biophys. Res. Commun. 2024, 739, 150598 10.1016/j.bbrc.2024.150598. [ DOI ] [ PubMed ] [ Google Scholar ] Tian Y.; Zhao Q.; Wu H.; Guo J.; Wu H. VWA2 protein molecular mechanism predicts colorectal cancer: Promoting cell invasion and migration by inhibiting NK cell activation. Int. J. Biol. Macromol. 2024, 279, 135394 10.1016/j.ijbiomac.2024.135394. [ DOI ] [ PubMed ] [ Google Scholar ] López-Cortés R.; Muinelo-Romay L.; Fernández-Briera A.; Gil Martín E. High-Throughput Mass Spectrometry Analysis of N-Glycans and Protein Markers after FUT8 Knockdown in the Syngeneic SW480/SW620 Colorectal Cancer Cell Model. J. Proteome Res. 2024, 23 (4), 1379–1398. 10.1021/acs.jproteome.3c00833. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Kong A. S.-Y.; Maran S.; Loh H.-S. Navigating the interplay between BCL-2 family proteins, apoptosis, and autophagy in colorectal cancer. Advances in Cancer Biology - Metastasis 2024, 11, 100126 10.1016/j.adcanc.2024.100126. [ DOI ] [ Google Scholar ] El Boustani M.; Mouawad N.; Alezz M. A. AP3M2: A key regulator from the nervous system modulates autophagy in colorectal cancer. Tissue Cell 2024, 91, 102593 10.1016/j.tice.2024.102593. [ DOI ] [ PubMed ] [ Google Scholar ] Deng R.; Liu Y.; Wu X.; Zhao N.; Deng J.; Pan T.; Cao L.; Zhan F.; Qiao X. Probing the interaction of hesperidin showing antiproliferative activity in colorectal cancer cells and human hemoglobin. Int. J. Biol. Macromol. 2024, 281, 136078 10.1016/j.ijbiomac.2024.136078. [ DOI ] [ PubMed ] [ Google Scholar ] Tanaka A.; Ogawa M.; Zhou Y.; Namba K.; Hendrickson R. C.; Miele M. M.; Li Z.; Klimstra D. S.; Buckley P. G.; Gulcher J.; et al. Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures. Cell Reports 2024, 43 (2), 113810 10.1016/j.celrep.2024.113810. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Ren Y.; Yue Y.; Li X.; Weng S.; Xu H.; Liu L.; Cheng Q.; Luo P.; Zhang T.; Liu Z.; et al. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy. International Immunopharmacology 2024, 142, 113147 10.1016/j.intimp.2024.113147. [ DOI ] [ PubMed ] [ Google Scholar ] Wang X.-Y.; Xu Y.-M.; Lau A. T. Y. Proteogenomics in Cancer: Then and Now. J. Proteome Res. 2023, 22 (10), 3103–3122. 10.1021/acs.jproteome.3c00196. [ DOI ] [ PubMed ] [ Google Scholar ] Rodriguez H.; Zenklusen J. C.; Staudt L. M.; Doroshow J. H.; Lowy D. R. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell 2021, 184 (7), 1661–1670. 10.1016/j.cell.2021.02.055. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Montero-Calle A.; Garranzo-Asensio M.; Poves C.; Sanz R.; Dziakova J.; Peláez-García A.; de los Ríos V.; Martinez-Useros J.; Fernández-Aceñero M. J.; Barderas R. In-Depth Proteomic Analysis of Paraffin-Embedded Tissue Samples from Colorectal Cancer Patients Revealed TXNDC17 and SLC8A1 as Key Proteins Associated with the Disease. J. Proteome Res. 2024, 23, 4802. 10.1021/acs.jproteome.3c00749. [ DOI ] [ PubMed ] [ Google Scholar ] Liu J.; Chang X.; Qian L.; Chen S.; Xue Z.; Wu J.; Luo D.; Huang B.; Fan J.; Guo T.; et al. Proteomics-Derived Biomarker Panel Facilitates Distinguishing Primary Lung Adenocarcinomas With Intestinal or Mucinous Differentiation From Lung Metastatic Colorectal Cancer. Molecular & Cellular Proteomics 2024, 23 (5), 100766 10.1016/j.mcpro.2024.100766. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Jiang F.; Wu G.; Yang H.; Zhang Y.; Shen X.; Tao L. Diethylaminoethyl-dextran and monocyte cell membrane coated 1,8-cineole delivery system for intracellular delivery and synergistic treatment of atherosclerosis. Int. J. Biol. Macromol. 2023, 253, 127365 10.1016/j.ijbiomac.2023.127365. [ DOI ] [ PubMed ] [ Google Scholar ] Srivastava U.; Kanchan S.; Kesheri M.; Gupta M. K.; Singh S.. Chapter 2 - Types of omics data: Genomics, metagenomics, epigenomics, transcriptomics, proteomics, metabolomics, and phenomics. In Integrative Omics; Gupta M. K., Katara P., Mondal S., Singh R. L., Eds.; Academic Press, 2024; pp 13–34. [ Google Scholar ] Malekpour M.; Salarikia S. R.; Golabi F.; Sheida F.; Kashkooli M.; Midjani F.; Soleymanjahi S. Su1493 EXPLORING THE GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC INTERSECTIONS IN CHOLANGIOCARCINOMA: A DRUG DISCOVERY APPROACH. Gastroenterology 2024, 166 (5), S-763–S-764. 10.1016/S0016-5085(24)02236-4. [ DOI ] [ Google Scholar ] Wang T.; Liu Y.; Liu Q.; Cummins S.; Zhao M. Integrative proteomic analysis reveals potential high-frequency alternative open reading frame-encoded peptides in human colorectal cancer. Life Sciences 2018, 215, 182–189. 10.1016/j.lfs.2018.11.018. [ DOI ] [ PubMed ] [ Google Scholar ] Peng Q.; Deng Y.; Li G.; Li J.; Zheng P.; Xiong Q.; Li J.; Chen Y.; Ge F. Quantitative Proteomics Reveal the Mechanism of MiR-138–5p Suppressing Cervical Cancer via Targeting ZNF385A. J. Proteome Res. 2024, 23 (8), 3659–3673. 10.1021/acs.jproteome.4c00349. [ DOI ] [ PubMed ] [ Google Scholar ] Ji S.; Fang H.; Guan J.; He K.; Yang Q. Immunoproteomics Reveal Different Characteristics for the Prognostic Markers of Intratumoral-Infiltrating CD3+ T Lymphocytes and Immunoscore in Colorectal Cancer. Laboratory Investigation 2024, 104 (12), 102159 10.1016/j.labinv.2024.102159. [ DOI ] [ PubMed ] [ Google Scholar ] Romero-Elías M.; González-Cutre D.; Ruiz-Casado A.; Ferriz R.; Navarro-Espejo N.; Beltrán-Carrillo V. J. Exploring the perceived benefits of a motivational exercise program (FIT-CANCER) in colorectal cancer patients during chemotherapy treatment: A qualitative study from self-determination theory. European Journal of Integrative Medicine 2024, 65, 102328 10.1016/j.eujim.2023.102328. [ DOI ] [ Google Scholar ] Nie C.; Shaw I.; Chen C. Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review. Journal of Pharmaceutical Analysis 2023, 13 (12), 1429–1451. 10.1016/j.jpha.2023.08.009. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Hung W.-H.; Zheng J.-H.; Lee K.-C.; Cho E.-C. Doxorubicin conjugated AuNP/biopolymer composites facilitate cell cycle regulation and exhibit superior tumor suppression potential in KRAS mutant colorectal cancer. J. Biotechnol. 2019, 306, 149–158. 10.1016/j.jbiotec.2019.09.015. [ DOI ] [ PubMed ] [ Google Scholar ] Irham L. M.; Wong H. S.-C.; Chou W.-H.; Adikusuma W.; Mugiyanto E.; Huang W.-C.; Chang W.-C. Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Pharmacol. Res. 2020, 161, 105203 10.1016/j.phrs.2020.105203. [ DOI ] [ PubMed ] [ Google Scholar ] Khan F.; Akhtar S.; Kamal M. A. Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management. Curr. Med. Chem. 2023, 30 (3), 271–285. 10.2174/0929867329666220610090405. [ DOI ] [ PubMed ] [ Google Scholar ] Kuo C.-N.; Liao Y.-M.; Kuo L.-N.; Tsai H.-J.; Chang W.-C.; Yen Y. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. Journal of the Formosan Medical Association 2020, 119 (12), 1731–1741. 10.1016/j.jfma.2019.08.023. [ DOI ] [ PubMed ] [ Google Scholar ] Patil K. C.; Yakhmi J. V.. Chapter 13 - Nanotechnology for cancer therapy: Invading the mechanics of cancer. In Nanobiomaterials in Cancer Therapy; Grumezescu A. M., Ed.; William Andrew Publishing, 2016; pp 395–470. [ Google Scholar ] Marques C. F.; Marques M. M.. Pharmacometabolomics in Drug Discovery and Development. In Systems Medicine; Wolkenhauer O., Ed.; Academic Press, 2021; pp 480–500. [ Google Scholar ] Yan S.-K.; Liu R.-H.; Jin H.-Z.; Liu X.-R.; Ye J.; Shan L.; Zhang W.-D. “Omics” in pharmaceutical research: overview, applications, challenges, and future perspectives. Chinese Journal of Natural Medicines 2015, 13 (1), 3–21. 10.1016/S1875-5364(15)60002-4. [ DOI ] [ PubMed ] [ Google Scholar ] Vasile C.Chapter 1 - Polymeric Nanomaterials: Recent Developments, Properties and Medical Applications. In Polymeric Nanomaterials in Nanotherapeutics; Vasile C., Ed.; Elsevier, 2019; pp 1–66. [ Google Scholar ] Yoo B. C.; Kim K.-H.; Woo S. M.; Myung J. K. Clinical multi-omics strategies for the effective cancer management. Journal of Proteomics 2018, 188, 97–106. 10.1016/j.jprot.2017.08.010. [ DOI ] [ PubMed ] [ Google Scholar ] Poornima P.; Kumar J. D.; Zhao Q.; Blunder M.; Efferth T. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol. Res. 2016, 111, 290–302. 10.1016/j.phrs.2016.06.018. [ DOI ] [ PubMed ] [ Google Scholar ] Chen M. X.; Wang S.-Y.; Kuo C.-H.; Tsai I. L. Metabolome analysis for investigating host-gut microbiota interactions. Journal of the Formosan Medical Association 2019, 118, S10–S22. 10.1016/j.jfma.2018.09.007. [ DOI ] [ PubMed ] [ Google Scholar ] Cheng W.; Li F.; Yang R. The Roles of Gut Microbiota Metabolites in the Occurrence and Development of Colorectal Cancer: Multiple Insights for Potential Clinical Applications. Gastro Hep Advances 2024, 3 (6), 855–870. 10.1016/j.gastha.2024.05.012. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Saita K.; Tanabe K.; Akabane S.; Amano S.; Okamura H. P28–3 Clinical application of portable fNIRS to measure cognitive impairment after chemotherapy in a colorectal cancer patient. Annals of Oncology 2024, 35, S1374–S1375. 10.1016/j.annonc.2024.07.402. [ DOI ] [ Google Scholar ] Amelimojarad M.; AmeliMojarad M.; Nazemalhosseini-Mojarad E. Exosomal noncoding RNAs in colorectal cancer: An overview of functions, challenges, opportunities, and clinical applications. Pathology - Research and Practice 2022, 238, 154133 10.1016/j.prp.2022.154133. [ DOI ] [ PubMed ] [ Google Scholar ] Echle A.; Ghaffari Laleh N.; Quirke P.; Grabsch H. I.; Muti H. S.; Saldanha O. L.; Brockmoeller S. F.; van den Brandt P. A.; Hutchins G. G. A.; Richman S. D.; et al. Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application. ESMO Open 2022, 7 (2), 100400 10.1016/j.esmoop.2022.100400. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Muñoz M.; Possi B.; Suarez L.; Llenas V.; Sabatini L.; Palazzi J.; Perroud H. P-416 Value of liquid biopsy in taking faster medical decisions in colorectal cancer patients. Its clinical application in an Argentinian cancer institution. Annals of Oncology 2023, 34, S158. 10.1016/j.annonc.2023.04.472. [ DOI ] [ Google Scholar ] Dalal N.; Jalandra R.; Sharma M.; Prakash H.; Makharia G. K.; Solanki P. R.; Singh R.; Kumar A. Omics technologies for improved diagnosis and treatment of colorectal cancer: Technical advancement and major perspectives. Biomedicine & Pharmacotherapy 2020, 131, 110648 10.1016/j.biopha.2020.110648. [ DOI ] [ PubMed ] [ Google Scholar ] Abstracts from USCAP 2019: Pathobiology (including pan-genomic/pan-proteomic approaches to cancer) (1735–1770). Mod. Pathol. 2019, 32, 1–30. 10.1038/s41379-019-0232-x. [ DOI ] [ PubMed ] [ Google Scholar ] Xie Z.; Lin H.; Huang Y.; Wang X.; Lin H.; Xu M.; Wu J.; Wu Y.; Shen H.; Zhang Q.; et al. BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer. Eur. J. Cancer 2024, 210, 114278 10.1016/j.ejca.2024.114278. [ DOI ] [ PubMed ] [ Google Scholar ] Li J.; Tian J.; Liu Y.; Liu Z.; Tong M. Personalized analysis of human cancer multi-omics for precision oncology. Computational and Structural Biotechnology Journal 2024, 23, 2049–2056. 10.1016/j.csbj.2024.05.011. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Stenzinger A.; Edsjö A.; Ploeger C.; Friedman M.; Fröhling S.; Wirta V.; Seufferlein T.; Botling J.; Duyster J.; Akhras M.; et al. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology 2022, 84, 242–254. 10.1016/j.semcancer.2021.05.026. [ DOI ] [ PubMed ] [ Google Scholar ] Mauri G.; Patelli G.; Sartore-Bianchi A.; Abrignani S.; Bodega B.; Marsoni S.; Costanzo V.; Bachi A.; Siena S.; Bardelli A. Early-onset cancers: Biological bases and clinical implications. Cell Reports Medicine 2024, 5 (9), 101737 10.1016/j.xcrm.2024.101737. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Boussios S.; Ozturk M. A.; Moschetta M.; Karathanasi A.; Zakynthinakis-Kyriakou N.; Katsanos K. H.; Christodoulou D. K.; Pavlidis N. The Developing Story of Predictive Biomarkers in Colorectal Cancer. J. Personalized Med. 2019, 9, 12. 10.3390/jpm9010012. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Deng E. Z.; Marino G. B.; Clarke D. J. B.; Diamant I.; Resnick A. C.; Ma W.; Wang P.; Ma’ayan A. Multiomics2Targets identifies targets from cancer cohorts profiled with transcriptomics, proteomics, and phosphoproteomics. Cell Reports Methods 2024, 4 (8), 100839 10.1016/j.crmeth.2024.100839. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Choi S.; An J.-Y.. Multiomics in cancer biomarker discovery and cancer subtyping. In Advances in Clinical Chemistry; Elsevier, 2024. [ DOI ] [ PubMed ] [ Google Scholar ] Islam Khan M. Z.; Tam S. Y.; Azam Z.; Law H. K. W. Proteomic profiling of metabolic proteins as potential biomarkers of radioresponsiveness for colorectal cancer. Journal of Proteomics 2022, 262, 104600 10.1016/j.jprot.2022.104600. [ DOI ] [ PubMed ] [ Google Scholar ] Coskun A.; Ertaylan G.; Pusparum M.; Van Hoof R.; Kaya Z. Z.; Khosravi A.; Zarrabi A. Advancing personalized medicine: Integrating statistical algorithms with omics and nano-omics for enhanced diagnostic accuracy and treatment efficacy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024, 1870 (7), 167339 10.1016/j.bbadis.2024.167339. [ DOI ] [ PubMed ] [ Google Scholar ] Hamdy N. M.; Zaki M. B.; Rizk N. I.; Abdelmaksoud N. M.; Abd-Elmawla M. A.; Ismail R. A.; Abulsoud A. I. Unraveling the ncRNA landscape that governs colorectal cancer: A roadmap to personalized therapeutics. Life Sciences 2024, 354, 122946 10.1016/j.lfs.2024.122946. [ DOI ] [ PubMed ] [ Google Scholar ] Fu D.; Zhang T.; Liu J.; Chang B.; Zhang Q.; Tan Y.; Chen X.; Tan L. Identification of adipocyte infiltration-related gene subtypes for predicting colorectal cancer prognosis and responses of immunotherapy/chemotherapy. Heliyon 2024, 10 (13), e33616 10.1016/j.heliyon.2024.e33616. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Zhang R.; Su C.; Jia Y.; Xing M.; Jin S.; Zong H. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer. Biomedicine & Pharmacotherapy 2024, 179, 117363 10.1016/j.biopha.2024.117363. [ DOI ] [ PubMed ] [ Google Scholar ] Almayahi B. A.; Sani S. F. A.; Tajuddin H. A.; Saad H. M.; Alhasan A.; Sim K. S. Structural and functional characterization of gamma-irradiation-enhanced nanocomposites for colorectal cancer therapy. J. Mol. Struct. 2025, 1321, 139859 10.1016/j.molstruc.2024.139859. [ DOI ] [ Google Scholar ] Qiao W.; Li S.; Luo L.; Chen M.; Zheng X.; Ye J.; Liang Z.; Wang Q.; Hu T.; Zhou L.; et al. Ce6-GFFY is a novel photosensitizer for colorectal cancer therapy. Genes & Diseases 2025, 12, 101441 10.1016/j.gendis.2024.101441. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Zhang Y.; Zhang Y.; Song J.; Cheng X.; Zhou C.; Huang S.; Zhao W.; Zong Z.; Yang L. Targeting the “tumor microenvironment”: RNA-binding proteins in the spotlight in colorectal cancer therapy. International Immunopharmacology 2024, 131, 111876 10.1016/j.intimp.2024.111876. [ DOI ] [ PubMed ] [ Google Scholar ] Yang C.; Ming H.; Li B.; Liu S.; Chen L.; Zhang T.; Gao Y.; He T.; Huang C.; Du Z. A pH and glutathione-responsive carbon monoxide-driven nano-herb delivery system for enhanced immunotherapy in colorectal cancer. J. Controlled Release 2024, 376, 659–677. 10.1016/j.jconrel.2024.10.043. [ DOI ] [ PubMed ] [ Google Scholar ] Tuo Z.; Zhang Y.; Li D.; Wang Y.; Wu R.; Wang J.; Yu Q.; Ye L.; Shao F.; Wusiman D.; et al. Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review. Pharmacol. Res. 2024, 206, 107302 10.1016/j.phrs.2024.107302. [ DOI ] [ PubMed ] [ Google Scholar ] Bi H.; Weng X. Single-Cell Epigenomics and Proteomics Methods Integrated in Multiomics. Fund. Res. 2024, 10.1016/j.fmre.2023.11.014. [ DOI ] [ Google Scholar ] Piñero J.; Rodriguez Fraga P. S.; Valls-Margarit J.; Ronzano F.; Accuosto P.; Lambea Jane R.; Sanz F.; Furlong L. I. Genomic and proteomic biomarker landscape in clinical trials. Computational and Structural Biotechnology Journal 2023, 21, 2110–2118. 10.1016/j.csbj.2023.03.014. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Gong Y.; Liu Y.; Wang T.; Li Z.; Gao L.; Chen H.; Shu Y.; Li Y.; Xu H.; Zhou Z.; et al. Age-Associated Proteomic Signatures and Potential Clinically Actionable Targets of Colorectal Cancer. Molecular & Cellular Proteomics 2021, 20, 100115 10.1016/j.mcpro.2021.100115. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Plattner C.; Lamberti G.; Blattmann P.; Kirchmair A.; Rieder D.; Loncova Z.; Sturm G.; Scheidl S.; Ijsselsteijn M.; Fotakis G.; et al. Functional and spatial proteomics profiling reveals intra- and intercellular signaling crosstalk in colorectal cancer. iScience 2023, 26 (12), 108399 10.1016/j.isci.2023.108399. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Yang X.-L.; Shi Y.; Zhang D.-D.; Xin R.; Deng J.; Wu T.-M.; Wang H.-M.; Wang P.-Y.; Liu J.-B.; Li W.; et al. Quantitative proteomics characterization of cancer biomarkers and treatment. Molecular Therapy - Oncolytics 2021, 21, 255–263. 10.1016/j.omto.2021.04.006. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Hakami Z. H. Biomarker discovery and validation for gastrointestinal tumors: A comprehensive review of colorectal, gastric, and liver cancers. Pathology - Research and Practice 2024, 255, 155216 10.1016/j.prp.2024.155216. [ DOI ] [ PubMed ] [ Google Scholar ] Nisar N.; Mir S. A.; Kareem O.; Pottoo F. H.. Chapter 4 - Proteomics approaches in the identification of cancer biomarkers and drug discovery. In Proteomics; Ali S., Majid S., Rehman M. U., Eds.; Academic Press, 2023; pp 77–120. [ Google Scholar ] Hassan Khanzada M.; Khan A.; Khan K.; Jalal K.; Aghayeva S.; Uddin R. A reverse vaccinomics approach for the designing of novel immunogenic multi-epitope vaccine construct against gas gangrene and related colorectal cancer for Clostridium septicum DSM 7534. Hum. Immunol. 2024, 85 (6), 111169 10.1016/j.humimm.2024.111169. [ DOI ] [ PubMed ] [ Google Scholar ] Alaoui-Jamali M. A.; Dupré I.; Qiang H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resistance Updates 2004, 7 (4), 245–255. 10.1016/j.drup.2004.06.004. [ DOI ] [ PubMed ] [ Google Scholar ] Wei X.; Su R.; Yang M.; Pan B.; Lu J.; Lin H.; Shu W.; Wang R.; Xu X. Quantitative proteomic profiling of hepatocellular carcinoma at different serum alpha-fetoprotein level. Translational Oncology 2022, 20, 101422 10.1016/j.tranon.2022.101422. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Rao J.; Wang T.; Wang K.; Qiu F. Integrative analysis of metabolomics and proteomics reveals mechanism of berberrubine-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 2024, 488, 116992 10.1016/j.taap.2024.116992. [ DOI ] [ PubMed ] [ Google Scholar ] Wang Y.; Ding G.; Chu C.; Cheng X.-D.; Qin J.-J. Genomic biology and therapeutic strategies of liver metastasis from gastric cancer. Critical Reviews in Oncology/Hematology 2024, 202, 104470 10.1016/j.critrevonc.2024.104470. [ DOI ] [ PubMed ] [ Google Scholar ] Guan X.; Bu F.; Fu Y.; Zhang H.; Xiang H.; Chen X.; Chen T.; Wu X.; Wu K.; Liu L.; et al. Immunogenic Peptides Putatively from Intratumor Microbes. Opportunities for Colorectal Cancer Treatment. iScience 2024, 27, 111338 10.1016/j.isci.2024.111338. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article. Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article references. Articles from ACS Pharmacology & Translational Science are provided here courtesy of American Chemical Society ACTIONS View on publisher site PDF (4.5 MB) Cite Collections Permalink PERMALINK Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Add to Collections Create a new collection Add to an existing collection Name your collection * Choose a collection Unable to load your collection due to an error Please try again Add Cancel Follow NCBI NCBI on X (formerly known as Twitter) NCBI on Facebook NCBI on LinkedIn NCBI on GitHub NCBI RSS feed Connect with NLM NLM on X (formerly known as Twitter) NLM on Facebook NLM on YouTube National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894 Web Policies FOIA HHS Vulnerability Disclosure Help Accessibility Careers NLM NIH HHS USA.gov Back to Top